var title_f30_12_30912="Diagnosis acute cholecystitis";
var content_f30_12_30912=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Algorithm for the diagnosis of acute cholecystitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 540px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GB: gallbladder; U/S: ultrasound.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_12_30912=[""].join("\n");
var outline_f30_12_30912=null;
var title_f30_12_30913="Scleral thinning RPC";
var content_f30_12_30913=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F52035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F52035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Scleral thinning in relapsing polychondritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The dark area in the sclera is typical of the scleromalacia that may occur in patients with relapsing polychondritis. This darkening results from thinning of the sclera, which allows the pigment of the underlying choroid to be seen. Inflammatory manifestations such as episcleritis, scleritis, conjunctivitis, and iritis may precede scleromalacia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; 2012 American College of Rheumatology. Used with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_12_30913=[""].join("\n");
var outline_f30_12_30913=null;
var title_f30_12_30914="Patient information: Multinodular goiter (The Basics)";
var content_f30_12_30914=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17222\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/45/42704\">",
"         Overactive thyroid",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?22/9/22674\">",
"         Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/4/23618\">",
"         Patient information: Thyroid nodules (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/15/23794\">",
"         Patient information: Antithyroid drugs (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/6/3172\">",
"         Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/16/18691\">",
"         Patient information: Thyroid nodules (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Multinodular goiter (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/multinodular-goiter-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H10725256\">",
"      <span class=\"h1\">",
"       What is a multinodular goiter?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A multinodular goiter is a swelling in the neck. It is caused by abnormal growth of the thyroid gland, plus 1 or more growths called &ldquo;thyroid nodules.&rdquo; Thyroid nodules are round or oval-shaped growths in the thyroid gland. The thyroid gland is in the middle of the neck.",
"     </p>",
"     <p>",
"      Thyroid nodules are common and not usually harmful to a person&rsquo;s health. But sometimes thyroid nodules are caused by a serious condition, such as cancer.",
"     </p>",
"     <p>",
"      The thyroid gland makes a hormone called &ldquo;thyroid hormone.&rdquo; Most thyroid nodules do not change the amount of thyroid hormone in the body. But some thyroid nodules cause the thyroid gland to make too much thyroid hormone. If a multinodular goiter has this type of thyroid nodules, it can cause symptoms (",
"      <a class=\"graphic graphic_figure graphicRef58509 \" href=\"mobipreview.htm?41/45/42704\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10725270\">",
"      <span class=\"h1\">",
"       What are the symptoms of a multinodular goiter?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with a multinodular goiter do not have symptoms. The swelling might be found during an imaging test, such as an X-ray, that is done for another reason. Or a blood test to check thyroid hormone levels might show that a person has too much thyroid hormone. Having too much thyroid hormone can be a sign of a multinodular goiter.",
"     </p>",
"     <p>",
"      Some people with a multinodular goiter feel or see a lump in their neck. Or they have symptoms from having too much thyroid hormone, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feeling worried or upset, or having trouble sleeping",
"       </li>",
"       <li>",
"        Feeling weak or tired",
"       </li>",
"       <li>",
"        Losing weight without trying",
"       </li>",
"       <li>",
"        Having a fast heartbeat",
"       </li>",
"       <li>",
"        Having frequent bowel movements",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If a multinodular goiter presses on the throat or airway, it can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trouble breathing -- Especially during physical activity, at night, or when reaching or bending",
"       </li>",
"       <li>",
"        Wheezing",
"       </li>",
"       <li>",
"        Coughing",
"       </li>",
"       <li>",
"        A choking feeling",
"       </li>",
"       <li>",
"        Trouble swallowing &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10725285\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor will want to make sure that the multinodular goiter is not going to harm your body. You need tests to find out if nodules in the goiter are causing your thyroid gland to make too much hormone. Your doctor will also check the nodules to see how big they are and if they need to be taken out.",
"     </p>",
"     <p>",
"      Tests usually include blood tests and an imaging test of the thyroid called an &ldquo;ultrasound.&rdquo; This test uses sound waves to create a picture of the inside of your body.",
"     </p>",
"     <p>",
"      Sometimes, people need more tests. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Fine needle aspiration &ndash; For this test, a doctor uses a thin needle to remove a small sample of tissue from 1 nodule in the goiter, usually the largest. He or she might take tissue from more than 1 nodule. Then, another doctor looks at the tissue under a microscope.",
"       </li>",
"       <li>",
"        Thyroid scan &ndash; People get this test only if they have too much thyroid hormone in the body. For this test, a person gets a pill or a shot with a small amount of a radioactive substance. Then a special camera takes a picture of the thyroid gland. This test is not safe for women who are pregnant or breastfeeding.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10725302\">",
"      <span class=\"h1\">",
"       How is a multinodular goiter treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many multinodular goiters do not need treatment. If the nodules are small and do not look harmful, your doctor might watch and wait to see if the swelling gets bigger or needs to be treated.",
"     </p>",
"     <p>",
"      A multinodular goiter needs treatment if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        It causes the thyroid gland to make too much hormone",
"       </li>",
"       <li>",
"        It causes problems with breathing, swallowing, or other body functions &ndash; or is very large",
"       </li>",
"       <li>",
"        It contains cancer",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Treatments for multinodular goiter include: &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Antithyroid medicines &ndash; If your thyroid blood tests show that the thyroid gland is making too much thyroid hormone, doctors can use medicines such as",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/53/16213?source=see_link\">",
"         methimazole",
"        </a>",
"        (MMI) (brand name: Tapazole&reg;) and",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/31/30196?source=see_link\">",
"         propylthiouracil",
"        </a>",
"        (also called PTU) to lower the amount of thyroid hormone it makes. These medicines control thyroid hormone levels until doctors can do other treatments.",
"       </li>",
"       <li>",
"        Medicines to help with symptoms caused by too much thyroid hormone, such as",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/27/2486?source=see_link\">",
"         atenolol",
"        </a>",
"        (brand name: Tenormin&reg;)",
"       </li>",
"       <li>",
"        Surgery to remove the multinodular goiter",
"       </li>",
"       <li>",
"        Radioactive iodine &ndash; Radioactive iodine comes in a pill or liquid that you swallow. It has a small amount of radiation in it. The radiation treats the problem by destroying a lot of the thyroid gland, so it does not make so much hormone. Radioactive iodine is used only to treat nodules that make too much thyroid hormone. It is not safe for women who are pregnant or breastfeeding.",
"       </li>",
"       <li>",
"        Injections (shots) of alcohol to shrink nodules, or laser treatment to destroy them. The alcohol used in this treatment is not the kind people drink.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10725317\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, talk with your doctor or nurse. He or she can make sure your multinodular goiter is not making too much thyroid hormone before you get pregnant. &nbsp;",
"     </p>",
"     <p>",
"      Women who are pregnant should not be treated with radioactive iodine. This is because radioactive iodine can cause serious harm to a baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10725332\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/4/23618?source=see_link\">",
"       Patient information: Thyroid nodules (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/9/22674?source=see_link\">",
"       Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/16/18691?source=see_link\">",
"       Patient information: Thyroid nodules (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/6/3172?source=see_link\">",
"       Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/15/23794?source=see_link\">",
"       Patient information: Antithyroid drugs (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/12/30914?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17222 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-0B2EC3AACF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_12_30914=[""].join("\n");
var outline_f30_12_30914=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10725256\">",
"      What is a multinodular goiter?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10725270\">",
"      What are the symptoms of a multinodular goiter?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10725285\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10725302\">",
"      How is a multinodular goiter treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10725317\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10725332\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17222\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/45/42704\">",
"      Overactive thyroid",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/15/23794?source=related_link\">",
"      Patient information: Antithyroid drugs (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/6/3172?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/9/22674?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/16/18691?source=related_link\">",
"      Patient information: Thyroid nodules (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/4/23618?source=related_link\">",
"      Patient information: Thyroid nodules (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_12_30915="Lichen planus trachyonychia";
var content_f30_12_30915=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Trachyonychia induced by lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_12_30915=[""].join("\n");
var outline_f30_12_30915=null;
var title_f30_12_30916="Magnesium L-aspartate hydrochloride: Drug information";
var content_f30_12_30916=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Magnesium L-aspartate hydrochloride: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/38/11876?source=see_link\">",
"    see \"Magnesium L-aspartate hydrochloride: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/7/28788?source=see_link\">",
"    see \"Magnesium L-aspartate hydrochloride: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Maginex&trade; DS [OTC];",
"     </li>",
"     <li>",
"      Maginex&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F190759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Electrolyte Supplement, Oral;",
"     </li>",
"     <li>",
"      Magnesium Salt",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F190751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake for Magnesium: Dosage is in terms of elemental magnesium (IOM, 1997):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     RDA:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     19-30 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Females: 310 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pregnant females: 350 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Lactation: 310 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Males: 400 mg daily",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     &ge;31 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Females: 320 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pregnant females: 360 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Lactation: 320 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Males: 420 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       OTC labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Dietary supplement (dosage in terms of magnesium-L-aspartate hydrochloride salt):",
"     </b>",
"     Adults: Oral: One packet or 2 tablets (1230 mg) up to 3 times daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F3013496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/7/28788?source=see_link\">",
"      see \"Magnesium L-aspartate hydrochloride: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake for Magnesium: Dosage is in terms of elemental magnesium (IOM, 1997):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-6 months: Adequate intake: 30 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-12 months: Adequate intake: 75 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: RDA: 80 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: RDA: 130 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-13 years: RDA: 240 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14-18 years: RDA:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Females: 360 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pregnant females: 400 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Lactation: 360 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Males: 410 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F190752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F190753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, magnesium is renally excreted. Use caution; accumulation of magnesium in renal impairment may lead to magnesium toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F190741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules for solution, oral [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maginex&trade; DS: 1230 mg/packet (30s) [sugar free; lemon flavor; equivalent to elemental magnesium 122 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, enteric coated, oral [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maginex&trade;: 615 mg [sugar free; equivalent to elemental magnesium 61 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3013440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F190744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules: Mix each packet prior to administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, enteric coated: Do not crush or chew",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F190743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dietary supplement",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F190757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Gastrointestinal: Abdominal cramps, diarrhea (excessive oral doses), gas formation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F190746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F190735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Constipation (self-medication, OTC use): Appropriate use: For occasional use only; serious side effects may occur with prolonged use. For use only under the supervision of a physician in patients with kidney dysfunction, sodium or magnesium restricted diets, abdominal pain/nausea/vomiting, or with a sudden change in bowel habits which has persisted for &gt;2 weeks.  If rectal bleeding develops or a bowel movement does not occur after use, discontinue use and consult a healthcare provider.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular disease: Use with extreme caution in patients with myasthenia gravis or other neuromuscular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; accumulation of magnesium may lead to magnesium intoxication.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F190738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfacalcidol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., magnesium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral magnesium salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Magnesium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Magnesium Salts may decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Magnesium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3013482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Magnesium crosses the placenta; serum concentrations in the fetus are similar to those in the mother (Osada, 2002; Idama, 1998).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F190747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Magnesium is found in breast milk; concentrations remain constant during the first year of lactation and are not influenced by dietary intake under normal conditions. Magnesium requirements are the same in lactating and nonlactating females (IOM, 1997).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F190748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with food. Whole grains, legumes, and dark-green leafy vegetables are dietary sources of magnesium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5164862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Maginex DS Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1230 mg (30): $19.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Maginex Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     615 mg (100): $22.23",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F190742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum magnesium: 1.5-2.5 mg/dL; slightly different ranges are reported by different laboratories",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3013489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Magnesium is important as a cofactor in many enzymatic reactions in the body involving protein synthesis and carbohydrate metabolism (at least 300 enzymatic reactions require magnesium). Actions on lipoprotein lipase have been found to be important in reducing serum cholesterol and on sodium/potassium ATPase in promoting polarization (eg, neuromuscular functioning).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15156149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Excretion: Urine (IOM, 1997)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bashuk RG and Krendel DA, &ldquo;Myasthenia Gravis Presenting as Weakness After Magnesium Administration,&rdquo;",
"      <i>",
"       Muscle Nerve",
"      </i>",
"      , 1990, 13(8):708-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/12/30916/abstract-text/2385256/pubmed\" id=\"2385256\" target=\"_blank\">",
"        2385256",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gams JG, &ldquo;Clinical Significance of Magnesium: A Review,&rdquo;",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1987, 21(3):240-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/12/30916/abstract-text/3552543/pubmed\" id=\"3552543\" target=\"_blank\">",
"        3552543",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Idama TO and Lindow SW, \"Magnesium Sulphate: A Review of Clinical Pharmacology Applied to Obstetrics,\"",
"      <i>",
"       Br J Obstet Gynaecol",
"      </i>",
"      , 1998, 105(3):260-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/12/30916/abstract-text/9532984/pubmed\" id=\"9532984\" target=\"_blank\">",
"        9532984",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride",
"      </i>",
"      , National Academy of Sciences, Washington, DC, 1997.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osada H, Watanabe Y, Nishimura Y, et al, \"Profile of Trace Element Concentrations in the Feto-Placental Unit in Relation to Fetal Growth,\"",
"      <i>",
"       Acta Obstet Gynecol Scand",
"      </i>",
"      , 2002, 81(10):931-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/12/30916/abstract-text/12366483/pubmed\" id=\"12366483\" target=\"_blank\">",
"        12366483",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9965 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-3FB984B900-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_12_30916=[""].join("\n");
var outline_f30_12_30916=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190750\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190759\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190751\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3013496\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190752\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190753\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190741\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3013440\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190744\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190743\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190757\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190746\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190735\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299636\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190738\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3013482\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190747\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190748\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5164862\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190742\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3013489\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15156149\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9965\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9965|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/38/11876?source=related_link\">",
"      Magnesium L-aspartate hydrochloride: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/7/28788?source=related_link\">",
"      Magnesium L-aspartate hydrochloride: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_12_30917="Familial polyposis Gross";
var content_f30_12_30917=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple colorectal polyps in patients with familial adenomatous polyposis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross specimen of the colon from a patient with familial adenomatous polyposis shows innumerable small polyps.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_12_30917=[""].join("\n");
var outline_f30_12_30917=null;
var title_f30_12_30918="HP granulomas Light";
var content_f30_12_30918=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Granulomas in hypersensitivity pneumonitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph shows noncaseating granulomas (arrows) which, in this case, have a sarcoid-like appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_12_30918=[""].join("\n");
var outline_f30_12_30918=null;
var title_f30_12_30919="Low grade spleen laceration";
var content_f30_12_30919=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F71599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F71599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Low grade splenic laceration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 422px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lewis J Kaplan, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_12_30919=[""].join("\n");
var outline_f30_12_30919=null;
var title_f30_12_30920="Paraganglioma Light";
var content_f30_12_30920=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Paraganglioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 227px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power and high power light micrographs showing round and polygonal epithelioid cells arranged in a trabecular pattern.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Silloo B Kapadia, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_12_30920=[""].join("\n");
var outline_f30_12_30920=null;
var title_f30_12_30921="Cardiac implantable electronic device lead removal";
var content_f30_12_30921=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiac implantable electronic device lead removal",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/12/30921/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/12/30921/contributors\">",
"     Ann C Garlitski, MD, FACC, FHRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/12/30921/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/12/30921/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/12/30921/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/12/30921/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/12/30921/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As more people are living longer with more significant cardiac disease, permanent pacemakers (PPMs) and implantable cardioverter-defibrillators (ICDs) are being inserted more frequently. Beginning early in the 21",
"    <sup>",
"     st",
"    </sup>",
"    century, there has also been an expansion in the indications for cardiac implantable electronic devices (CIED, a term which includes PPMs and ICDs), and device therapy has become more complex, frequently involving multiple leads per patient. As such, there are occasions when it is necessary to remove a device and any associated leads.",
"   </p>",
"   <p>",
"    The most common indications for lead removal are infection, venous occlusion, advisory or recall as a result of (potential) lead malfunction, or mechanical lead failure. Lead management involves the assessment of risks and benefits of whether or not to remove the lead based on the individual clinical condition of the patient as well as lead characteristics.",
"   </p>",
"   <p>",
"    This topic will discuss the indications for lead removal, lead removal procedure requirements, outcomes, and potential complications of lead removal. A more comprehensive discussion of CIED infection, complications of CIED implantation, and device malfunction is found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44345?source=see_link\">",
"     \"Infections involving cardiac implantable electronic devices\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21737?source=see_link\">",
"     \"Pacing system malfunction: Evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3462569\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standardized definitions related to lead removal have been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/1\">",
"     1",
"    </a>",
"    ]. Lead removal is a general term which encompasses removal of a cardiac implantable electronic device (CIED) lead using any technique, while lead explantation and lead extraction are terms with more specific definitions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lead explantation &mdash; Lead explantation is defined as removal of a lead that has been implanted for less than one year via the implant vein using only the tools typically supplied for lead implantation in combination with manual traction.",
"     </li>",
"     <li>",
"      Lead extraction &mdash; Lead extraction is generally a more complicated procedure which meets one of the following criteria:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The lead is removed with the assistance of specialized equipment (eg, laser sheaths) regardless of the implant duration. (See",
"      <a class=\"local\" href=\"#H2425159645\">",
"       'Lead removal procedure'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The lead is removed via a site other than the implant vein.",
"     </li>",
"     <li>",
"      The lead being removed has been implanted for more than one year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2425159238\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common indications for lead removal are infection, venous occlusion, mechanical lead failure (often resulting in improper pacemaker function or inappropriate ICD shocks), or advisory or recall as a result of (potential) lead malfunction. As a result of the complex nature of these cases, recommendations for lead removal apply only to those patients in whom the benefits outweigh the risks when assessed on individual patient factors and operator specific experience and outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2425159213\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections, which can result in CIED device and lead removal, can generally be grouped into two major categories (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44345?source=see_link\">",
"     \"Infections involving cardiac implantable electronic devices\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pocket infection",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      device associated endocarditis",
"     </li>",
"     <li>",
"      Bacteremia without an alternative source (particularly Staph aureus) or bacteremia which persists or recurs despite appropriate antimicrobial therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3729624\">",
"    <span class=\"h3\">",
"     Pocket infection and/or device-associated endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lead removal (along with device removal) is indicated in persons with infection that directly involves any part of the cardiac implantable electronic device (CIED) system. Two studies that span the years of 1990 through 2003 reveal concerning rises in rates of infections that parallel and even exceed the rates of device implantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The possible reasons for this increase are a result of higher infection rates in generator changes (than in initial implants) and the likely overall poorer health of the patients who are being implanted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/6\">",
"     6",
"    </a>",
"    ]. Untreated device-related infection is associated with mortality rates ranging from 31 to 66 percent, a rate that is two to threefold higher than the mortality seen in patients treated with device system extraction and antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/7-12\">",
"     7-12",
"    </a>",
"    ]. In most situations, eradication of CIED infection requires complete removal of the entire system (ie, all hardware including the generator and leads).",
"   </p>",
"   <p>",
"    The device along with the leads should be removed whenever there is evidence of pocket infection with or without associated bacteremia, or lead infection, which is essentially synonymous with device-related endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/3\">",
"     3",
"    </a>",
"    ]. Device-related endocarditis is a particularly strong indication for CIED device and lead removal since failure to remove an infected lead is associated with a high rate of relapsed infection and mortality even with a full course of appropriate antibiotic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/7,8,13-18\">",
"     7,8,13-18",
"    </a>",
"    ]. Pocket infections, however, also require CIED device and lead explantation, even without evidence of deeper infection, as in most cases the risks of recurrent infection outweigh the risks of extraction.",
"   </p>",
"   <p>",
"    In a retrospective single-center study of all consecutive cases of CIED infections between 1991 and 2008 (416 patients), device removal complications were associated with increased mortality at 30 days (HR 4.33, 95% CI 1.47-12.70) and at one year (HR 3.77, 95% CI 1.88-7.55) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/19\">",
"     19",
"    </a>",
"    ]. However, when compared with the group of patients treated initially with antimicrobial therapy with either delayed device removal or no device removal, immediate device removal was associated with a threefold decrease in one-year mortality (HR 0.35, 95% CI 0.16-0.75). In multivariate analysis, antimicrobial therapy without device removal was associated with a significant increase in 30-day mortality (HR 6.97, 95% CI 1.36-35.60). (See",
"    <a class=\"local\" href=\"#H991790\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although system infection is the strongest indication for lead removal, each clinical case must be evaluated based on individual comorbidities and long-term outcomes. There are occasional situations (eg, critically ill patients, patients with an overall poor prognosis or limited life expectancy) where chronic suppression with antibiotics is favored rather than CIED extraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/2,20\">",
"     2,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In cases of pocket infection without bacteremia or endocarditis, lead retention may be considered in patients in whom severe comorbidities or extenuating circumstances exist (eg, extreme frailty) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/9\">",
"     9",
"    </a>",
"    ]. Even some patients with lead infection or endocarditis are occasionally managed without device and lead explantation. These are usually extremely frail patients with limited life expectancy or patients refusing device removal. In such cases, however, long-term oral suppressive antibiotics are usually the alternative to lead removal. These patients are, however, at high risk of failure with relapse and increased mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/3,21\">",
"     3,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3729675\">",
"    <span class=\"h4\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations apply to patients with documented pocket infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    device-associated endocarditis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend lead removal in the case of documented CIED system infection, as evidenced by [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/3,22,23\">",
"       3,22,23",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Valvular or lead-associated endocarditis",
"     </li>",
"     <li>",
"      Pocket infection as evidenced by pocket abscess",
"     </li>",
"     <li>",
"      Device erosion through the skin",
"     </li>",
"     <li>",
"      Skin adherence (pre-erosion)",
"     </li>",
"     <li>",
"      Chronically-draining",
"      <span class=\"nowrap\">",
"       sinus/fistula",
"      </span>",
"      from the pocket to the skin",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest lead removal in patients with valvular endocarditis, even without definite involvement of the lead(s)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      device.",
"     </li>",
"     <li>",
"      Lead removal is not necessary if there is only a superficial or incisional infection without involvement of the device or leads [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3729733\">",
"    <span class=\"h3\">",
"     Bacteremia without obvious CIED device infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all patients with an implanted cardiac device who develop bacteremia end up with infection involving their device. On occasion, however, ongoing bacteremia can result in CIED colonization that is not evident on imaging evaluation. In such patients, should all other sources of infection be excluded, CIED removal may be required.",
"   </p>",
"   <p>",
"    We recommended CIED explantation for patients with bacteremia even in the absence of evidence of device infection in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Staph aureus bacteremia without an alternative source",
"     </li>",
"     <li>",
"      Bacteremia due to any pathogen that persists or recurs without an alternative source despite appropriate antibiotic therapy",
"     </li>",
"     <li>",
"      When patients undergo valve replacement or repair for infective endocarditis (thus eliminating a source for potential relapse)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Situations in which retention of the device may be attempted include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with bacteremia from a defined source other than the device (including valvular infection) if the following conditions are met: there is no clinical or TEE evidence of lead infection; there is no evidence of pocket infection; and the device has not been recently manipulated. Such patients may be treated with antibiotics for the bacteremic disease and then observed for relapse. Subsequent unexplained relapse suggests device infection and a need to extract the system [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/3,24,25\">",
"       3,24,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with superficial cellulitis at the incision in whom the infection does not appear to extend into the generator pocket may be treated without device removal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/3\">",
"       3",
"      </a>",
"      ]. However, this distinction is often difficult to make, and patients managed with device retention require close observation. In general, device retention is usually reserved for patients in whom device removal poses significant risks (eg, patients with major comorbidities, long standing devices, or who require continuous pacemaker support). Aggressive antibiotic therapy should be administered with this approach. If there is evidence of recurrent, persistent, or progressive infection despite appropriate intravenous antibiotic therapy, the system should be removed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2425159595\">",
"    <span class=\"h2\">",
"     Thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper extremity venous thrombosis in and of itself is not an indication for lead removal. Several clinical studies have revealed that venous stenoses and occlusion following endovascular pacing and defibrillator lead placement is a common occurrence and is frequently asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. However, there are situations in which the thrombosis may cause limiting symptoms, the most concerning, albeit least common, being superior vena cava syndrome. If the patient is to undergo stent deployment as treatment, lead removal should be performed prior to stent placement to avoid entrapment of the lead between the stent and the vessel wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/29-34\">",
"     29-34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19338?source=see_link&amp;anchor=H25#H25\">",
"     \"Malignancy-related superior vena cava syndrome\", section on 'Endovascular stents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The other more common circumstance in which venous occlusion would be an indication for lead removal is when the occlusion does not allow",
"    <span class=\"nowrap\">",
"     placement/upgrade",
"    </span>",
"    of a device. There are also some situations (eg, a contralateral AV fistula, shunt, vascular access port or mastectomy) in which proceeding with a contralateral CIED implant is not advised.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2425159602\">",
"    <span class=\"h2\">",
"     Malfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lead removal should be performed in patients with leads that, due to their design or their failure, may pose an immediate threat to the patients if left in place. Such a threat might include failure of a pacemaker to properly pace in a pacemaker-dependent patient or the delivery of inappropriate implantable cardioverter-defibrillator shocks. A more detailed discussion regarding lead failure is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=see_link&amp;anchor=H9#H9\">",
"     \"Implantable cardioverter-defibrillators: Complications\", section on 'Lead failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2425159623\">",
"    <span class=\"h2\">",
"     Advisory/recall",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decision-making in response to an advisory is extraordinarily complex as the data to assess the risk-benefit ratio are often not readily available and are outside the scope of this discussion. Nonetheless, when the response to an advisory or recall results in lead removal, then we can learn from the resultant treatment. Data accumulated following several prominent advisories and recalls of CIED leads have provided valuable information for clinicians:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Telectronics Accufix pacing leads were recalled in November 1994 after two deaths and two nonfatal injuries were reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/35\">",
"       35",
"      </a>",
"      ]. In a report from a multicenter study and worldwide registry of extraction of the Telectronics Accufix atrial \"J\" lead from a total of 4023 patients, major complication rates were approximately 3 and 4 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/35\">",
"       35",
"      </a>",
"      ]. The mortality rates, resulting primarily from central venous tear or myocardial perforation, were 0.2 and 0.4 percent, respectively. The risk of a major complication increased progressively with implant duration.",
"     </li>",
"     <li>",
"      In October 2007 Medtronic suspended distribution of the Sprint Fidelis lead due to growing concerns regarding an abnormally high fracture rate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/36\">",
"       36",
"      </a>",
"      ]. In a retrospective, multicenter review of 3169 patients with Sprint Fidelis leads, the reported failure rates (failure defined as a sudden rise in impedance or inappropriate shocks) were 5, 11, and 17 percent at three, four, and five years post-implantation, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/37\">",
"       37",
"      </a>",
"      ]. Predictors of higher risk of lead failure were female sex, axillary or subclavian venous access, and previous lead failure.",
"      <br/>",
"      <br/>",
"      The clinician response to this has been variable, with some only removing leads that demonstrate malfunction, while others have prophylactically removed the lead even without evidence of malfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In one report from the Canadian Heart Rhythm Society Device Advisory Committee, which reviewed 248 cases of lead removal versus 220 cases of lead abandonment as a result of the Sprint Fidelis advisory, the overall risk of complications was significantly greater in those who underwent lead removal at the time of revision than in those whose leads were abandoned (19.8 versus 8.6 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/38\">",
"       38",
"      </a>",
"      ]. There was one death in each group.",
"     </li>",
"     <li>",
"      In a retrospective cohort study of consecutive patients at five high-volume centers between 2005 and 2009 evaluating 349 Sprint Fidelis leads (mean duration of implant was 27.5 months) extracted from 348 patients, all leads were completely removed with no major procedural complications or deaths [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In December 2011, St. Jude Medical announced that the US Food and Drug Administration classified its voluntary medical device advisory letter to clinicians regarding the performance of Riata&reg; and Riata&reg; ST Silicone Defibrillation Leads as a Class I Recall [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/40\">",
"       40",
"      </a>",
"      ]. The decision to pursue conservative monitoring versus lead extraction in this situation is challenging and multifactorial without any firm evidence to guide the decision.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The decision to remove an apparently normally-functioning lead or leads in response to a manufacturer's or regulatory body's recall or warning is complex and should be performed in close consultation with an electrophysiologist with consideration for the patient's overall clinical status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2425159630\">",
"    <span class=\"h2\">",
"     Lead upgrade or abandonment",
"    </span>",
"    &nbsp;&mdash;&nbsp;On occasion, previously placed leads may be capped and abandoned during CIED upgrade. Abandoned leads, however, pose a risk of interference with the placement or operation of another CIED and may need to be removed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of contraindications, we suggest removal of abandoned leads at the time of an indicated CIED procedure if implantation of the new device would result in greater than four unilateral leads or greater than five leads through the superior vena cava. In patients who do not meet these criteria, lead abandonment may be considered for leads that are functional and sterile but superfluous.",
"   </p>",
"   <p>",
"    It is important to reiterate that these indications for lead extraction presume that there is an appropriate extraction environment which satisfies recommendations on operator and facility training and volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2425159638\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients, lead removal is associated with risks that are exceeded by the perceived benefits of the procedure. However, there are some relative contraindications to percutaneous transvenous lead removal, which include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of calcification (visible by radiography) involving the lead in the atrium or superior vena cava",
"     </li>",
"     <li>",
"      Unavailability of required personnel or equipment",
"     </li>",
"     <li>",
"      The patient not being a suitable candidate for emergent thoracotomy",
"     </li>",
"     <li>",
"      Known anomalous placement of leads through structures other than normal venous and cardiac structures (eg, subclavian artery, aorta, pleura, atrial or ventricular wall or mediastinum)",
"     </li>",
"     <li>",
"      Lead placement through a systemic venous atrium or systemic ventricle",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional techniques, including surgical backup, may be used if the clinical scenario is compelling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2425159645\">",
"    <span class=\"h1\">",
"     LEAD REMOVAL PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lead removal is generally a complex procedure that requires a significant amount of advance preparation. Knowledge of the patient's comorbidities, prior",
"    <span class=\"nowrap\">",
"     invasive/surgical",
"    </span>",
"    history (eg, prior cardiac surgery or presence of an inferior vena cava filter), and lead characteristics such as lead length, diameter, and adapter information are required. The need for pacemaker support (ie, in a pacemaker-dependent patient) and ongoing device therapy must be assessed.",
"   </p>",
"   <p>",
"    Extraction of leads is technically more challenging than generator removal and carries a risk of vascular",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiac injury. This risk is largely due to the fibrous connections that develop between the leads and the vascular wall and endocardial surface. As the lead is separated from adhesions to veins and endocardial surfaces, these structures can tear. Due to the risk of endovascular injury, we recommend that lead extraction be undertaken in centers with experience and appropriate facilities including back-up cardiothoracic surgery on site.",
"   </p>",
"   <p>",
"    The connections between the lead and endovascular structures can be more substantial with ICD leads than pacemaker leads. ICD leads are larger and have additional components (coils) that provide a greater surface area for adherence.",
"   </p>",
"   <p>",
"    Adhesions between endovascular structures and leads become stronger over time. Leads that have been in place less than one to two years can usually be extracted with relatively low risk. Leads in place for greater periods of time become progressively more difficult to extract with a higher risk of endovascular injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3463013\">",
"    <span class=\"h2\">",
"     Techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a variety of techniques for lead removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct (manual) traction &mdash; A stylet is inserted into the hollow center of the lead, extending close to the distal electrode. A stylet designed for lead extraction locks into place, providing support and allowing the application of direct traction to remove the lead. Leads that are isodiametric (the same diameter along the length of the lead) and less than one year old can potentially be removed by manual traction alone.",
"     </li>",
"     <li>",
"      Telescoping sheaths &mdash; Specially designed sheaths extend over the lead, dissecting it away from the vascular wall and endocardium.",
"     </li>",
"     <li>",
"      Excimer laser sheaths &mdash; The laser in these sheaths dissolves, rather than tears, the fibrous attachments of the electrodes.",
"     </li>",
"     <li>",
"      Surgical removal &mdash; Cardiotomy with surgical removal is usually reserved for cases in which transcutaneous approaches have failed. In some patients with large vegetations attached to the lead (eg, &gt;2.5 cm), surgical removal may be the preferred initial approach in order to minimize the risk of pulmonary embolism. Reports suggest that percutaneous removal even in the setting of large vegetations can be accomplished without clinically significant pulmonary embolism. (See",
"      <a class=\"local\" href=\"#H2425159391\">",
"       'Outcomes'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients, frequently younger patients, will develop earlier and greater fibrotic ingrowth around the electrode tip than is seen in the average patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/42\">",
"     42",
"    </a>",
"    ]. In patients with extensive fibrosis around the electrode tip or along the length of the lead within the vasculature, lead removal becomes a more complex procedure because it requires freeing the lead from sites of adherence to the myocardium and venous endothelium. Early techniques involved manual traction that was often unsuccessful for chronically implanted leads and carried a high risk of myocardial avulsion, cardiac tamponade, and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lead removal tools have been developed to offer countertraction in order to improve the success of the procedure. The contemporary array of equipment includes locking stylets, nonpowered \"mechanical\" sheaths, radiofrequency powered sheaths (electrosurgical unit), excimer laser powered sheaths, and a rotational cutting blade sheath [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/41\">",
"     41",
"    </a>",
"    ]. Sheaths operate with simple, manual mechanical action (nonpowered) or additional power (as noted above) and may be used alone or within a second sheath as a telescoping system. The aim of powered sheaths is to advance along the lead with reduced traction and counterpressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/46\">",
"     46",
"    </a>",
"    ]. These tools are used to break fibrous adhesions along the course of the lead so that the lead may be removed, usually with no or minimal damage to the vein or myocardium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2425159653\">",
"    <span class=\"h2\">",
"     Operator experience",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lead extraction should be performed by trained and experienced clinician staff using specialized equipment and only following appropriate patient preparation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Registry data support the inverse relationship between complication rates and operator experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. Complications were 1.5 times more likely to occur during the first 10 cases, shown to have the steepest decline during the first 30 cases, and to continue to decline with further experience, up to 400 cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H991790\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2425159660\">",
"    <span class=\"h2\">",
"     Facility requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lead removal is performed under intravenous sedation or general anesthesia in the electrophysiology laboratory or operating room with high quality fluoroscopy. A complete armamentarium of extraction tools as well as surgical instruments should be at hand. The ability to perform transthoracic and transesophageal echocardiography must be immediately available. Because of the potential for serious complications, personnel and resources to perform emergency thoracotomy and cardiopulmonary bypass should be in place.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2425159391\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Success rates for lead removal are variable as a result of case selection as well as differences in reporting (ie, complete versus partial removal). Large series of patients who have undergone lead extraction have reported high success rates (95 to 99 percent) and low complication rates (&lt;1 percent), although major complications do occur, including cardiac tamponade, vessel laceration, traumatic tricuspid regurgitation, and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/35,51-58\">",
"     35,51-58",
"    </a>",
"    ]. However, the likelihood of complications varies with operator experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/41,49,51\">",
"     41,49,51",
"    </a>",
"    ]. Thus, the results of individual studies, which often reflect the outcomes of experienced operators with high volumes in",
"    <span class=\"nowrap\">",
"     tertiary/quaternary",
"    </span>",
"    care centers, are not generalizable to all settings.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an early report of investigational lead extraction between 1995 and 1999 using laser sheaths in 2561 pacing and ICD leads in 1684 patients at 89 sites, 90 percent of leads were completely removed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/51\">",
"       51",
"      </a>",
"      ]. Major complications (tamponade, hemothorax, pulmonary embolism, lead migration, and death) were observed in 1.9 percent with death in 0.8 percent. Minor complications (including avulsion of vein or myocardium, laceration, arm swelling, and pocket hematoma) were reported in 1.4 percent.",
"     </li>",
"     <li>",
"      In the LExICon study in which 2405 leads in 1449 consecutive patients at 13 centers were extracted via a laser between 2004 and 2007, complete lead removal was reported in 96.5 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/55\">",
"       55",
"      </a>",
"      ]. Procedure failure was higher in leads implanted for greater than 10 years and when performed in low volume centers. All cause in-hospital mortality was 1.86 percent and increased to 4.3 percent when lead removal was associated with endocarditis.",
"     </li>",
"     <li>",
"      In 279 procedures involving the removal of 445 leads between 2000 and 2009 at a single center where all leads were removed via manual traction (without the assistance of extraction sheaths), clinical success was approximately 85 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/59\">",
"       59",
"      </a>",
"      ]. This success rate is similar to published data on lead removal using direct traction or telescoping sheaths from a decade previous [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/18\">",
"       18",
"      </a>",
"      ]. The highest clinical success (approximately 95 percent) was observed in patients with leads implanted less than 2.6 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Comparative data come from a randomized trial of 301 patients with 465 leads in place for an average of 65 to 69 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/53\">",
"       53",
"      </a>",
"      ]. Complete lead extraction was achieved significantly more often using a laser sheath compared with traction through a telescoping sheath (94 versus 64 percent). Major complications occurred in 5 of 244 laser lead extractions and in 2 of 221 non-laser lead extractions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar success rates have been reported for the extraction of coronary sinus leads used for cardiac resynchronization therapy. In a single-center, retrospective review of 145 patients undergoing extraction of coronary sinus leads (147 leads total), 99 percent of leads were successfully extracted, 70 percent using manual traction alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/60\">",
"     60",
"    </a>",
"    ]. Cardiac tamponade in one patient (0.7 percent) was the only major complication reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H991790\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;While CIED lead removal is performed without difficulty in most patients, complications can occur. Most of the complications are traumatic and related to the lead itself (ie, vascular injury, cardiac perforation resulting in cardiac tamponade, tricuspid regurgitation), although embolization of thrombus or vegetation from the lead is also a concern. When performed by experienced operators, mortality is usually less than 1 percent of patients, with major complications seen in 2 to 3 percent of patients. (See",
"    <a class=\"local\" href=\"#H2425159391\">",
"     'Outcomes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Risk factors for a complication during lead removal include younger patient age, female sex, presence of calcification involving the leads on chest radiograph, and the presence of multiple leads [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/35,51,61\">",
"     35,51,61",
"    </a>",
"    ]. In general, implantable cardioverter-defibrillator (ICD) leads are more challenging to remove than pacemaker leads as a result of the presence of coils, which tend to be more adherent to vasculature and myocardium. In turn, dual coil ICD leads are more difficult to remove than single coil ICD leads. Leads with a passive fixation mechanism are more difficult to extract than those that are active [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/35,53\">",
"     35,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H275292\">",
"    <span class=\"h3\">",
"     Tricuspid regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence, risk factors, and outcome of traumatic tricuspid regurgitation (TR) following right ventricular lead removal were evaluated in a single-center prospective study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/62\">",
"     62",
"    </a>",
"    ]. Over a five-year period during which 237 leads were removed from 208 patients, traumatic TR occurred in 19 patients (9.1 percent) and was severe in 14. Nine of these 14 patients developed new right-sided heart failure: two required surgical tricuspid valve repair, five were treated medically, and two died from complications related to heart failure. Multivariate analysis identified three independent risk factors for traumatic TR: use of a laser sheath, use of both a laser sheath and lasso, and female sex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H275417\">",
"    <span class=\"h3\">",
"     Pulmonary embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concern has been expressed that percutaneous lead extraction in the presence of large vegetations might precipitate pulmonary embolism (PE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/13,63-65\">",
"     13,63-65",
"    </a>",
"    ]. However, clinically relevant PE appears to be rare even with vegetations &gt;10 mm in size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/3,13,21,66-69\">",
"     3,13,21,66-69",
"    </a>",
"    ]. The lack of clinically relevant PE has been reported in several cohort studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of 53 cases of pacemaker lead endocarditis, 29 patients with 49 leads bearing vegetations with a mean size of 17.8 mm underwent successful transvenous removal using locking stylets and sheaths with no clinically apparent PEs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/68\">",
"       68",
"      </a>",
"      ]. Pacemaker leads with larger vegetations (mean size 22.4 mm) were removed by open cardiac surgery in 24 patients, three of whom died.",
"     </li>",
"     <li>",
"      In a single center study of percutaneous lead removal (215 leads in 100 patients) in the setting of intracardiac vegetations, either on the leads or on the valves and ranging in size from 0.2 to 4.0 cm (mean 1.6 cm) in diameter, embolization of vegetation material, which measured &gt;2 cm before extraction, was witnessed in only two cases with a third case that was presumed to have embolized (97 percent overall success rate for removal without embolization) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/70\">",
"       70",
"      </a>",
"      ]. In spite of the apparent embolization, all three patients recovered completely.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these limited data, we recommend balancing the small risk of PE against the hazards of cardiac surgery in determining how to remove electrodes bearing large vegetations that exceed 10 mm in size. There are no current guidelines to assist in this decision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H992143\">",
"    <span class=\"h1\">",
"     DEVICE REPLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;With regard to CIED replacement, issues to be considered include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Where the new device should be implanted",
"     </li>",
"     <li>",
"      When the new device should be implanted",
"     </li>",
"     <li>",
"      How to manage the patient between explantation and reimplantation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, 30 to 50 percent of patients in some series have not required replacement of the device; thus, the decision to do so should be weighed carefully [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/3,71\">",
"     3,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H992150\">",
"    <span class=\"h2\">",
"     Location",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever possible, the new pacemaker or ICD should be implanted at a different site from the explanted infected system. In most cases, this means reimplantation on the opposite side of the chest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H992157\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal timing for reimplantation is not known. However, in patients with uncomplicated pocket infections (ie, no evidence of bacteremia or endocarditis), the new device can be implanted at a new location after control of local infection if blood cultures after device removal remain negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/3,71\">",
"     3,71",
"    </a>",
"    ]. This early reimplantation approach is usually reserved for patients who require continuous pacemaker support (ie, are \"pacemaker-dependent\").",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H992164\">",
"    <span class=\"h2\">",
"     Interim management",
"    </span>",
"    &nbsp;&mdash;&nbsp;When reimplantation of a new device is delayed, management is based upon the purpose of the device and the patient's overall clinical condition.",
"   </p>",
"   <p>",
"    For patients with cardiac pacemakers, the following options are available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For pacemaker-dependent patients who require continuous pacemaker support, a temporary transvenous pacing system can be used. Temporary transvenous pacing is continued until blood cultures are negative and endocardial infection has been controlled, which usually requires at least two weeks of parenteral therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/13-15,72,73\">",
"       13-15,72,73",
"      </a>",
"      ]. A new permanent transvenous pacer can then be placed, and the definitive course of antibiotics completed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30921/abstract/3,16\">",
"       3,16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21465?source=see_link\">",
"       \"Temporary cardiac pacing\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A new epicardial pacing system can be inserted immediately, particularly if the infected lead is extracted at the time of cardiotomy.",
"     </li>",
"     <li>",
"      Some patients who are not pacemaker-dependent can be followed in a monitored setting without a temporary pacemaker until a new system is implanted.",
"     </li>",
"     <li>",
"      In some cases, the balance of risks and benefits may not justify reimplantation. Such decisions are made on an individual basis in consultation with an arrhythmia specialist. They are based upon the patients underlying rhythm, comorbidities, and procedural risks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with ICDs, the following options are available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Observation on continuous telemetry in a monitored setting until the new ICD is implanted.",
"     </li>",
"     <li>",
"      Immediate implantation of a new epicardial ICD system, particularly if the infected lead is extracted at cardiotomy.",
"     </li>",
"     <li>",
"      A wearable cardioverter-defibrillator. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/15/36088?source=see_link\">",
"       \"Wearable cardioverter-defibrillator\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some patients who received an ICD for the purpose of primary prevention SCD who have not yet received appropriate ICD therapy, discharge to a non-monitored setting to complete the antibiotic course is not unreasonable. Another alternative is to consider permanent discontinuation of ICD therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39672?source=see_link&amp;anchor=H13#H13\">",
"     \"Implantable cardioverter-defibrillators: Patient follow-up\", section on 'Discontinuation of ICD therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2425159675\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lead removal is a general term which encompasses removal of a cardiac implantable electronic device (CIED) lead using any technique, while lead explantation and lead extraction are terms with more specific definitions. (See",
"      <a class=\"local\" href=\"#H3462569\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common indications for lead removal are infection, venous occlusion, advisory or recall as a result of (potential) lead malfunction, or mechanical lead failure. As a result of the complex nature of these cases, recommendations for lead extraction apply only to those patients in whom the benefits outweigh the risks when assessed on individual patient factors and operator specific experience and outcomes. (See",
"      <a class=\"local\" href=\"#H2425159238\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with device-related endocarditis we recommend device and lead extraction (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3729624\">",
"       'Pocket infection and/or device-associated endocarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with pocket infection and bacteremia, we recommend device and lead extraction (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3729624\">",
"       'Pocket infection and/or device-associated endocarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with valvular endocarditis, even without definite involvement of the leads",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      device, we suggest lead removal (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3729624\">",
"       'Pocket infection and/or device-associated endocarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with pocket infection without bacteremia or endocarditis, we suggest device and lead extraction unless severe comorbidities or other extenuating circumstances exist (eg, extreme frailty, etc.) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Lead extraction may increase in difficulty and risk with the length of time since implantation and number of leads implanted. (See",
"      <a class=\"local\" href=\"#H3729624\">",
"       'Pocket infection and/or device-associated endocarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with recurrent or persistent Staph aureus bacteremia without an alternative source, we suggest the device and leads be explanted even in the absence of evidence of pocket infection or device-related endocarditis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3729733\">",
"       'Bacteremia without obvious CIED device infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with bacteremia due to any pathogen that persists or recurs without an alternative source despite appropriate antibiotic therapy, we suggest the device be explanted even in the absence of evidence of pocket infection or device-related endocarditis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3729733\">",
"       'Bacteremia without obvious CIED device infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients without evidence of pocket infection or endocarditis but who have bacteremia that meets the above suggestions for device explantation, we suggest lead extraction (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3729733\">",
"       'Bacteremia without obvious CIED device infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Due to the risk of endovascular injury, we recommend that lead extraction procedures be performed with thoracic surgery backup available. (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2425159238\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2425159645\">",
"       'Lead removal procedure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Upper extremity venous thrombosis, in and of itself, is not an indication for lead removal. However, there are situations in which the thrombosis may cause limiting symptoms, the most concerning, albeit least common, being superior vena cava syndrome. If the patient is to undergo stent deployment as treatment, lead removal should be performed prior to stent placement so as to avoid entrapment of the lead between the stent and the vessel wall. (See",
"      <a class=\"local\" href=\"#H2425159595\">",
"       'Thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lead removal should be performed in patients with leads that, due to their design or their failure, may pose an immediate threat to the patients if left in place. Such a threat might include failure of a pacemaker to properly pace in a pacemaker-dependent patient or the delivery of inappropriate implantable cardioverter-defibrillator shocks. (See",
"      <a class=\"local\" href=\"#H2425159602\">",
"       'Malfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision to remove an apparently normally-functioning lead or leads in response to a manufacturer's or regulatory body's recall or warning is complex and should be performed in close consultation with an electrophysiologist, with consideration for the patient's overall clinical status. (See",
"      <a class=\"local\" href=\"#H2425159623\">",
"       'Advisory/recall'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      On occasion, previously placed leads may be capped and abandoned during CIED upgrade. Abandoned leads, however, pose a risk of interference with the placement or operation of another CIED and may need to be removed. In the absence of contraindications, we suggest removal of abandoned leads at the time of an indicated CIED procedure if implantation of the new device would result in greater than four unilateral leads or greater than five leads through the superior vena cava (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2425159630\">",
"       'Lead upgrade or abandonment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Relative contraindications to percutaneous transvenous lead removal include the presence of calcification (visible by radiography) involving the lead in the atrium or superior vena cava, unavailability of required personnel or equipment, the patient not being a candidate for emergency thoracotomy, or anomalous lead placement. (See",
"      <a class=\"local\" href=\"#H2425159638\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lead removal is generally a complex procedure that requires a significant amount of advance preparation. Knowledge of the patient's comorbidities, prior",
"      <span class=\"nowrap\">",
"       invasive/surgical",
"      </span>",
"      history (eg, prior cardiac surgery or presence of an inferior vena cava filter), and lead characteristics such as lead length, diameter, and adapter information are required. The need for pacemaker support (ie, in a pacemaker-dependent patient) and ongoing device therapy must be assessed. (See",
"      <a class=\"local\" href=\"#H2425159645\">",
"       'Lead removal procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are a variety of techniques and equipment used for lead removal, including direct (manual) traction, locking stylets, nonpowered \"mechanical\" sheaths, radiofrequency powered sheaths (electrosurgical unit), excimer laser powered sheaths, and a rotational cutting blade sheath. (See",
"      <a class=\"local\" href=\"#H3463013\">",
"       'Techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Success rates for lead removal are variable and often reported in terms of complete versus partial removal. Large series of patients who have undergone lead extraction have reported high success rates (95 to 99 percent) and low complication rates (&lt;1 percent), although the results of individual studies, which often reflect the outcomes of experienced operators with high volumes in",
"      <span class=\"nowrap\">",
"       tertiary/quaternary",
"      </span>",
"      care centers, are not generalizable to all settings. (See",
"      <a class=\"local\" href=\"#H2425159391\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/1\">",
"      Love CJ, Wilkoff BL, Byrd CL, et al. Recommendations for extraction of chronically implanted transvenous pacing and defibrillator leads: indications, facilities, training. North American Society of Pacing and Electrophysiology Lead Extraction Conference Faculty. Pacing Clin Electrophysiol 2000; 23:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/2\">",
"      Wilkoff BL, Love CJ, Byrd CL, et al. Transvenous lead extraction: Heart Rhythm Society expert consensus on facilities, training, indications, and patient management: this document was endorsed by the American Heart Association (AHA). Heart Rhythm 2009; 6:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/3\">",
"      Baddour LM, Epstein AE, Erickson CC, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 2010; 121:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/4\">",
"      Cabell CH, Heidenreich PA, Chu VH, et al. Increasing rates of cardiac device infections among Medicare beneficiaries: 1990-1999. Am Heart J 2004; 147:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/5\">",
"      Voigt A, Shalaby A, Saba S. Rising rates of cardiac rhythm management device infections in the United States: 1996 through 2003. J Am Coll Cardiol 2006; 48:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/6\">",
"      Gould PA, Krahn AD, Canadian Heart Rhythm Society Working Group on Device Advisories. Complications associated with implantable cardioverter-defibrillator replacement in response to device advisories. JAMA 2006; 295:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/7\">",
"      Chua JD, Wilkoff BL, Lee I, et al. Diagnosis and management of infections involving implantable electrophysiologic cardiac devices. Ann Intern Med 2000; 133:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/8\">",
"      Baddour LM, Bettmann MA, Bolger AF, et al. Nonvalvular cardiovascular device-related infections. Circulation 2003; 108:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/9\">",
"      Samuels LE, Samuels FL, Kaufman MS, et al. Management of infected implantable cardiac defibrillators. Ann Thorac Surg 1997; 64:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/10\">",
"      Chamis AL, Peterson GE, Cabell CH, et al. Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators. Circulation 2001; 104:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/11\">",
"      Maytin M, Epstein LM, Henrikson CA. Lead extraction is preferred for lead revisions and system upgrades: when less is more. Circ Arrhythm Electrophysiol 2010; 3:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/12\">",
"      de Bie MK, van Rees JB, Thijssen J, et al. Cardiac device infections are associated with a significant mortality risk. Heart Rhythm 2012; 9:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/13\">",
"      Klug D, Lacroix D, Savoye C, et al. Systemic infection related to endocarditis on pacemaker leads: clinical presentation and management. Circulation 1997; 95:2098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/14\">",
"      Cacoub P, Leprince P, Nataf P, et al. Pacemaker infective endocarditis. Am J Cardiol 1998; 82:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/15\">",
"      Camus C, Leport C, Raffi F, et al. Sustained bacteremia in 26 patients with a permanent endocardial pacemaker: assessment of wire removal. Clin Infect Dis 1993; 17:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/16\">",
"      Karchmer AW, Longworth DL. Infections of intracardiac devices. Infect Dis Clin North Am 2002; 16:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/17\">",
"      Lewis AB, Hayes DL, Holmes DR Jr, et al. Update on infections involving permanent pacemakers. Characterization and management. J Thorac Cardiovasc Surg 1985; 89:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/18\">",
"      Bracke FA, Meijer A, van Gelder LM. Pacemaker lead complications: when is extraction appropriate and what can we learn from published data? Heart 2001; 85:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/19\">",
"      Le KY, Sohail MR, Friedman PA, et al. Impact of timing of device removal on mortality in patients with cardiovascular implantable electronic device infections. Heart Rhythm 2011; 8:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/20\">",
"      Baddour LM, Infectious Diseases Society of America's Emerging Infections Network. Long-term suppressive antimicrobial therapy for intravascular device-related infections. Am J Med Sci 2001; 322:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/21\">",
"      Sohail MR, Uslan DZ, Khan AH, et al. Infective endocarditis complicating permanent pacemaker and implantable cardioverter-defibrillator infection. Mayo Clin Proc 2008; 83:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/22\">",
"      Klug D, Wallet F, Lacroix D, et al. Local symptoms at the site of pacemaker implantation indicate latent systemic infection. Heart 2004; 90:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/23\">",
"      Verma A, Wilkoff BL. Intravascular pacemaker and defibrillator lead extraction: a state-of-the-art review. Heart Rhythm 2004; 1:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/24\">",
"      Duval X, Selton-Suty C, Alla F, et al. Endocarditis in patients with a permanent pacemaker: a 1-year epidemiological survey on infective endocarditis due to valvular and/or pacemaker infection. Clin Infect Dis 2004; 39:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/25\">",
"      Uslan DZ, Dowsley TF, Sohail MR, et al. Cardiovascular implantable electronic device infection in patients with Staphylococcus aureus bacteremia. Pacing Clin Electrophysiol 2010; 33:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/26\">",
"      Da Costa SS, Scalabrini Neto A, Costa R, et al. Incidence and risk factors of upper extremity deep vein lesions after permanent transvenous pacemaker implant: a 6-month follow-up prospective study. Pacing Clin Electrophysiol 2002; 25:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/27\">",
"      Korkeila P, Ylitalo A, Koistinen J, Airaksinen KE. Progression of venous pathology after pacemaker and cardioverter-defibrillator implantation: A prospective serial venographic study. Ann Med 2009; 41:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/28\">",
"      Haghjoo M, Nikoo MH, Fazelifar AF, et al. Predictors of venous obstruction following pacemaker or implantable cardioverter-defibrillator implantation: a contrast venographic study on 100 patients admitted for generator change, lead revision, or device upgrade. Europace 2007; 9:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/29\">",
"      Gula LJ, Ames A, Woodburn A, et al. Central venous occlusion is not an obstacle to device upgrade with the assistance of laser extraction. Pacing Clin Electrophysiol 2005; 28:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/30\">",
"      Cooper JM, Stephenson EA, Berul C, et al. Implantable Cardioverter-Defibrillator Lead Complications and Laser Extraction in Children and Young Adults with Congenital heart Disease. J Cardiovasc Electrophys 2003; 14:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/31\">",
"      Fischer A, Love B, Hansalia R, Mehta D. Transfemoral snaring and stabilization of pacemaker and defibrillator leads to maintain vascular access during lead extraction. Pacing Clin Electrophysiol 2009; 32:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/32\">",
"      Chan AW, Bhatt DL, Wilkoff BL, et al. Percutaneous treatment for pacemaker-associated superior vena cava syndrome. Pacing Clin Electrophysiol 2002; 25:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/33\">",
"      Worley SJ, Gohn DC, Pulliam RW. Over the wire lead extraction and focused force venoplasty to regain venous access in a totally occluded subclavian vein. J Interv Card Electrophysiol 2008; 23:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/34\">",
"      Henrikson CA, Alexander D, Ringel RE, Brinker JA. Laser recanalization of the subclavian vein. Pacing Clin Electrophysiol 2006; 29:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/35\">",
"      Kay GN, Brinker JA, Kawanishi DT, et al. Risks of spontaneous injury and extraction of an active fixation pacemaker lead: report of the Accufix Multicenter Clinical Study and Worldwide Registry. Circulation 1999; 100:2344.",
"     </a>",
"    </li>",
"    <li>",
"     Medtronic, Inc. Sprint Fidelis Model 6949 Lead Performance Physician Letter, dated October 15, 2007 file:// www.medtronic.com/product-advisories/physician/sprint-fidelis/ PROD-ADV-PHYS-OCT.htm (Accessed on February 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/37\">",
"      Birnie DH, Parkash R, Exner DV, et al. Clinical predictors of Fidelis lead failure: report from the Canadian Heart Rhythm Society Device Committee. Circulation 2012; 125:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/38\">",
"      Parkash R, Crystal E, Bashir J, et al. Complications associated with revision of Sprint Fidelis leads: report from the Canadian Heart Rhythm Society Device Advisory Committee. Circulation 2010; 121:2384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/39\">",
"      Maytin M, Love CJ, Fischer A, et al. Multicenter experience with extraction of the Sprint Fidelis implantable cardioverter-defibrillator lead. J Am Coll Cardiol 2010; 56:646.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm284390.htm (Accessed on January 26, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/41\">",
"      Smith MC, Love CJ. Extraction of transvenous pacing and ICD leads. Pacing Clin Electrophysiol 2008; 31:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/42\">",
"      Kennergren C. A European perspective on lead extraction: part I. Heart Rhythm 2008; 5:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/43\">",
"      Madigan NP, Curtis JJ, Sanfelippo JF, Murphy TJ. Difficulty of extraction of chronically implanted tined ventricular endocardial leads. J Am Coll Cardiol 1984; 3:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/44\">",
"      Lee ME, Chaux A, Matloff JM. Avulsion of a tricuspid valve leaflet during traction on an infected, entrapped endocardial pacemaker electrode. The role of electrode design. J Thorac Cardiovasc Surg 1977; 74:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/45\">",
"      Rettig G, Doenecke P, Sen S, et al. Complications with retained transvenous pacemaker electrodes. Am Heart J 1979; 98:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/46\">",
"      Deharo JC, Bongiorni MG, Rozkovec A, et al. Pathways for training and accreditation for transvenous lead extraction: a European Heart Rhythm Association position paper. Europace 2012; 14:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/47\">",
"      Byrd CL, Wilkoff BL, Love CJ, et al. Intravascular extraction of problematic or infected permanent pacemaker leads: 1994-1996. U.S. Extraction Database, MED Institute. Pacing Clin Electrophysiol 1999; 22:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/48\">",
"      Bracke FA, Meijer A, Van Gelder B. curve characteristics of pacing lead extraction with a laser sheath. Pacing Clin Electrophyiol 1998; 21:2309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/49\">",
"      Ghosh N, Yee R, Klein GJ, et al. Laser lead extraction: is there a learning curve? Pacing Clin Electophyiol 2005; 28:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/50\">",
"      Wilkoff BL, Byrd CL, Love CJ, et al. Trends in Intravascular Lead Extraction: Analysis of Data from 5339 Procedures in 10 Years. XIth World Symposium on Cardiac Pacing and Electrophysiology: Berlin. Pacing Clin Electrophysiol 1999; 22:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/51\">",
"      Byrd CL, Wilkoff BL, Love CJ, et al. Clinical study of the laser sheath for lead extraction: the total experience in the United States. Pacing Clin Electrophysiol 2002; 25:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/52\">",
"      Jones SO 4th, Eckart RE, Albert CM, Epstein LM. Large, single-center, single-operator experience with transvenous lead extraction: outcomes and changing indications. Heart Rhythm 2008; 5:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/53\">",
"      Wilkoff BL, Byrd CL, Love CJ, et al. Pacemaker lead extraction with the laser sheath: results of the pacing lead extraction with the excimer sheath (PLEXES) trial. J Am Coll Cardiol 1999; 33:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/54\">",
"      Roux JF, Pag&eacute; P, Dubuc M, et al. Laser lead extraction: predictors of success and complications. Pacing Clin Electrophysiol 2007; 30:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/55\">",
"      Wazni O, Epstein LM, Carrillo RG, et al. Lead extraction in the contemporary setting: the LExICon study: an observational retrospective study of consecutive laser lead extractions. J Am Coll Cardiol 2010; 55:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/56\">",
"      Hamid S, Arujuna A, Ginks M, et al. Pacemaker and defibrillator lead extraction: predictors of mortality during follow-up. Pacing Clin Electrophysiol 2010; 33:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/57\">",
"      Roux JF, Pag&eacute; P, Dubuc M, et al. Laser lead extraction: predictors of success and complications. Pacing Clin Electrophysiol 2007; 30:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/58\">",
"      Maytin M, Jones SO, Epstein LM. Long-term mortality after transvenous lead extraction. Circ Arrhythm Electrophysiol 2012; 5:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/59\">",
"      de Bie MK, Fouad DA, Borleffs CJ, et al. Trans-venous lead removal without the use of extraction sheaths, results of &gt;250 removal procedures. Europace 2012; 14:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/60\">",
"      di Cori A, Bongiorni MG, Zucchelli G, et al. Large, single-center experience in transvenous coronary sinus lead extraction: procedural outcomes and predictors for mechanical dilatation. Pacing Clin Electrophysiol 2012; 35:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/61\">",
"      Cooper JM, Stephenson EA, Berul CI, et al. Implantable cardioverter defibrillator lead complications and laser extraction in children and young adults with congenital heart disease: implications for implantation and management. J Cardiovasc Electrophysiol 2003; 14:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/62\">",
"      Franceschi F, Thuny F, Giorgi R, et al. Incidence, risk factors, and outcome of traumatic tricuspid regurgitation after percutaneous ventricular lead removal. J Am Coll Cardiol 2009; 53:2168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/63\">",
"      Victor F, De Place C, Camus C, et al. Pacemaker lead infection: echocardiographic features, management, and outcome. Heart 1999; 81:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/64\">",
"      Voet J, Vanderkerckhove Y, Muyldermans L, et al. Pacemaker lead infection: report of three cases and review of the literature. Heart 1999; 81:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/65\">",
"      Meier-Ewert HK, Gray ME, John RM. Endocardial pacemaker or defibrillator leads with infected vegetations: a single-center experience and consequences of transvenous extraction. Am Heart J 2003; 146:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/66\">",
"      Victor F, De Place C, Camus C, et al. Pacemaker lead infection: echocardiographic features, management, and outcome. Heart 1999; 81:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/67\">",
"      Nguyen KT, Neese P, Kessler DJ. Successful laser-assisted percutaneous extraction of four pacemaker leads associated with large vegetations. Pacing Clin Electrophysiol 2000; 23:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/68\">",
"      Ruttmann E, Hangler HB, Kilo J, et al. Transvenous pacemaker lead removal is safe and effective even in large vegetations: an analysis of 53 cases of pacemaker lead endocarditis. Pacing Clin Electrophysiol 2006; 29:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/69\">",
"      P&eacute;rez Baztarrica G, Gariglio L, Salvaggio F, et al. Transvenous extraction of pacemaker leads in infective endocarditis with vegetations &ge;20 mm: our experience. Clin Cardiol 2012; 35:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/70\">",
"      Grammes JA, Schulze CM, Al-Bataineh M, et al. Percutaneous pacemaker and implantable cardioverter-defibrillator lead extraction in 100 patients with intracardiac vegetations defined by transesophageal echocardiogram. J Am Coll Cardiol 2010; 55:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/71\">",
"      Sohail MR, Uslan DZ, Khan AH, et al. Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. J Am Coll Cardiol 2007; 49:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30921/abstract/72\">",
"      Arber N, Pras E, Copperman Y, et al. Pacemaker endocarditis. Report of 44 cases and review of the literature. Medicine (Baltimore) 1994; 73:299.",
"     </a>",
"    </li>",
"    <li>",
"     Eggimann P, Waldvogel F. Pacemaker and defibrillator infections. In: Infections Associated with Indwelling Medical Devices, Waldvogel FA, Bisno AL (Eds), American Society for Microbiology Press, Washington, DC 2000. p.247.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 971 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-9E6425AB09-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_12_30921=[""].join("\n");
var outline_f30_12_30921=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2425159675\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3462569\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2425159238\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2425159213\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3729624\">",
"      - Pocket infection and/or device-associated endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3729675\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3729733\">",
"      - Bacteremia without obvious CIED device infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2425159595\">",
"      Thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2425159602\">",
"      Malfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2425159623\">",
"      Advisory/recall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2425159630\">",
"      Lead upgrade or abandonment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2425159638\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2425159645\">",
"      LEAD REMOVAL PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3463013\">",
"      Techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2425159653\">",
"      Operator experience",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2425159660\">",
"      Facility requirements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2425159391\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H991790\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H275292\">",
"      - Tricuspid regurgitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H275417\">",
"      - Pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H992143\">",
"      DEVICE REPLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H992150\">",
"      Location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H992157\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H992164\">",
"      Interim management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2425159675\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=related_link\">",
"      Implantable cardioverter-defibrillators: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39672?source=related_link\">",
"      Implantable cardioverter-defibrillators: Patient follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44345?source=related_link\">",
"      Infections involving cardiac implantable electronic devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19338?source=related_link\">",
"      Malignancy-related superior vena cava syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21737?source=related_link\">",
"      Pacing system malfunction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21465?source=related_link\">",
"      Temporary cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/15/36088?source=related_link\">",
"      Wearable cardioverter-defibrillator",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_12_30922="Overview of immunosuppression in adult liver transplantation";
var content_f30_12_30922=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of immunosuppression in adult liver transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/12/30922/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/12/30922/contributors\">",
"     Norman L Sussman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/12/30922/contributors\">",
"     John M Vierling, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/12/30922/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/12/30922/contributors\">",
"     Robert S Brown, Jr, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/12/30922/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/12/30922/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/12/30922/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1994, the US Multicenter FK506 Liver Study Group published a paper comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (CSA) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    for immunosuppression after liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/1\">",
"     1",
"    </a>",
"    ]. The study was a landmark in the evolution of liver transplantation. First, the introduction stated that rejection remained an important cause of graft loss and death. Second, the paper reported that survival with cyclosporine and tacrolimus was similar, but that tacrolimus was associated with fewer episodes of steroid-resistant rejection. Third, it reported that tacrolimus was associated with excess adverse events, including nephrotoxicity and neurotoxicity.",
"   </p>",
"   <p>",
"    Liver transplantation has evolved substantially since that publication, and we have addressed many of the issues outlined in the 1994 study. Acute rejection is usually easy to manage, and we now try to balance the risk of rejection with the risk of drug toxicity. Our focus has shifted to avoiding the long-term complications of immunosuppression and recurrent liver disease.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    has become first-line immunosuppression in most liver transplant programs, and a number of supplemental drugs allow us to customize immunosuppression.",
"   </p>",
"   <p>",
"    This topic will provide an overview of the drugs used for immunosuppression following liver transplantation. The diagnosis and treatment of acute cellular rejection are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/28/37319?source=see_link\">",
"     \"Diagnosis of acute cellular rejection in liver transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/47/41718?source=see_link\">",
"     \"Treatment of acute cellular rejection in liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMMUNOBIOLOGY OF ACUTE REJECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organ rejection is a multistep process that includes alloantigen recognition, lymphocyte activation, clonal expansion, and graft inflammation (",
"    <a class=\"graphic graphic_figure graphicRef54486 \" href=\"mobipreview.htm?26/2/26658\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef60525 \" href=\"mobipreview.htm?2/9/2194\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Signal I: Alloantigen recognition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alloantigen recognition requires presentation of a foreign alloantigen along with a host major histocompatibility complex (MHC) molecule. Presentation is done by an antigen-presenting cell (APC). The antigen, bound to an MHC molecule, binds to the T-cell receptor. This is the first of three signals that are required for T-cell maturation and can be aborted by antilymphocyte antibodies. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Antibody therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Signal II: Lymphocyte activation (costimulation)",
"    </span>",
"    &nbsp;&mdash;&nbsp;T-cell activation requires costimulation, a process in which a number of ligands on the APC bind to a variety of T-cell receptors, including CD28, CD154, CD2, CD11a, and CD54. The T-cell receptor complex is internalized, and binds to immunophilin. Immunophilin stimulates calcineurin, which activates nuclear factor of T-cell activation (NFAT) by removing pyrophosphate. The activated NFAT then translocates to the nucleus where it drives IL-2 transcription. Two immunophilin targets, cyclophilin and FK-binding protein (FKBP), are targets of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , respectively. Both agents block calcineurin and are known collectively as calcineurin inhibitors (CNIs). (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Tacrolimus'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H10\">",
"     'Cyclosporine'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Signal III: Clonal expansion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newly synthesized IL-2 is secreted by T-cells and binds to IL-2 receptors (IL-2R) on the cell surface in an autocrine fashion, stimulating a burst of cell proliferation.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"     Basiliximab",
"    </a>",
"    and daclizumab, both monoclonal antibodies against the IL-2 receptor, block this signal.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    , which binds to the downstream mammalian target of rapamycin (mTOR), also acts at this step. Finally, the proliferation burst can be inhibited at the level of DNA synthesis by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Basiliximab and daclizumab'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H18\">",
"     'Sirolimus'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H22\">",
"     'Inhibitors of purine and pyrimidine synthesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;T-cell proliferation is associated with cell-mediated cytotoxicity and secretion of cytokines, chemokines, and adhesion molecules. The secreted mediators recruit additional inflammatory cells to the graft. The result is an inflammatory milieu with additional toxic and vasoactive mediators. Control of this step is possible with glucocorticoids and antilymphocyte antibodies. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Glucocorticoids'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H25\">",
"     'Antibody therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids suppress antibody and complement binding, upregulate IL-10 expression, and downregulate IL-2, IL-6, and interferon-gamma synthesis by T-cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. They have traditionally been the cornerstone of immunosuppression, and they remain the first line of initial therapy and treatment of acute allograft rejection in many centers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/47/41718?source=see_link\">",
"     \"Treatment of acute cellular rejection in liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Four steroid formulations are used commonly in transplantation:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    . These drugs have different relative potencies (",
"    <a class=\"graphic graphic_table graphicRef52276 \" href=\"mobipreview.htm?1/32/1547\">",
"     table 1",
"    </a>",
"    ). Steroid use varies among transplant centers, and there is no agreement on an ideal protocol. The protocol at Baylor College of Medicine is shown in the Table (",
"    <a class=\"graphic graphic_table graphicRef53128 \" href=\"mobipreview.htm?11/63/12283\">",
"     table 2",
"    </a>",
"    ). Another common regimen is a one gram bolus of methylprednisolone (Solu-Medrol) during the anhepatic phase, followed by 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    intravenously. Once the patient is able to take oral medications,",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    is switched to prednisone 20",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Tapering to zero is usually achieved over three to six months, although some centers leave patients on 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    indefinitely.",
"   </p>",
"   <p>",
"    Steroids are associated with a number of side effects including diabetes, fluid retention, hypertension, emotional lability, hyperlipidemia, cosmetic changes (acne, buffalo hump, etc), poor wound healing, susceptibility to infection, visual changes, cataracts, and osteopenia, and they may cause adrenal suppression that may persist up to the time of weaning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the side effects, steroid therapy increases hepatitis C virus (HCV) replication. The basis of this increase is controversial. Steroids may drive replication directly,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    they may permit more effective replication through immunosuppression. In vitro studies using a replicon system (which avoids the effect of the immune system) have yielded conflicting results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The controversy about steroid avoidance and tapering in HCV infected patients is discussed below. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Glucocorticoids and HCV'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Given the problems with glucocorticoids, many centers try to wean from steroids as early as possible. This must be done cautiously, since rapid steroid withdrawal can precipitate a flare of an underlying condition (eg, autoimmune hepatitis, inflammatory bowel disease, or hepatitis) or an episode of rejection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Glucocorticoids and HCV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cirrhosis secondary to hepatitis C virus (HCV) infection has become the leading indication for orthotopic liver transplant (OLT) in the United States. The ability of steroids to increase HCV replication has created concern about their use in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31530?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\", section on 'Disease course during glucocorticoid use'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a general rule, three options exist with regard to glucocorticoid use in patients with HCV:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maintain low dose steroids indefinitely (approximately 5",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"     </li>",
"     <li>",
"      Taper steroids slowly",
"     </li>",
"     <li>",
"      Avoid steroids",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most centers use the second strategy, although the first and third continue to be studied. If steroids are used, a flare of HCV infection with an increased viral load and increased aminotransferases should be anticipated during tapering. Slower tapering, addition of another immunosuppressive agent, and use of antiviral therapy are all strategies undergoing evaluation.",
"   </p>",
"   <p>",
"    Steroid-free immunosuppression is possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. It has the theoretical advantage of avoiding a steroid-related increase in viral replication with a subsequent flare during steroid withdrawal. The actual risk of steroid use in the setting of transplantation is incompletely understood. Studies have used a variety of designs and immunosuppression regimens, and rejection itself has a role in virus-induced cirrhosis with effects on long-term graft and patient survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/11-14\">",
"     11-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials have had variable results, as illustrated by the following examples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/9,10,15,16\">",
"     9,10,15,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 312 patients were assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      and glucocorticoids (arm 1, n = 80); tacrolimus, glucocorticoids, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil (MMF, arm 2, n = 79); or daclizumab induction, tacrolimus, and MMF (arm 3, n = 153) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/9\">",
"       9",
"      </a>",
"      ]. At one year follow-up, there were no differences in the groups with regard to patient and graft survival or HCV recurrence. However, freedom from rejection was significantly higher in arm 3 compared with arm 1 (93 versus 82 percent).",
"     </li>",
"     <li>",
"      A second trial addressed rejection and recurrent HCV in 89 patients assigned either to dual therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"       basiliximab",
"      </a>",
"      or to triple therapy with cyclosporine, basiliximab, and a steroid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/15\">",
"       15",
"      </a>",
"      ]. Recurrent HCV infection was seen in 97 percent of patients in both groups and viral loads at 6, 12, and 24 months were not statistically different. Protocol biopsies at 6, 12, and 24 months showed similar rates of rejection (17 to 21 percent). Portal inflammation and fibrosis scores were higher in the steroid group at two years, although only portal inflammation reached statistical significance.",
"     </li>",
"     <li>",
"      A third trial with 103 patients examined",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      monotherapy versus triple therapy (tacrolimus,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , and tapering",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/16\">",
"       16",
"      </a>",
"      ]. In that study, Ishak stage",
"      <span class=\"nowrap\">",
"       4/6",
"      </span>",
"      fibrosis was reached in more patients in the monotherapy group compared with the triple therapy group (31 versus 20 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 2009 meta-analysis included 21 randomized controlled trials with 2590 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/17\">",
"     17",
"    </a>",
"    ]. In that analysis, patients who did not receive steroids appeared to benefit with regard to overall acute rejection (if the steroid was replaced with an alternative agent), severe acute rejection, development of de novo diabetes mellitus, CMV infection, cholesterol levels, and the number of patients who received the allocated treatment. In patients with HCV, the steroid-free protocols were associated with lower rates of HCV recurrence, acute graft hepatitis, and treatment failure.",
"   </p>",
"   <p>",
"    In addition to potential benefits in patients with HCV, steroid-free regimens may also improve growth patterns in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While steroid-free immunosuppression is feasible, we remain unconvinced that these regimens confer sufficient value to warrant a change in protocol at any given transplant center for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trials cannot necessarily be compared since steroid dosing and tapering regimens vary widely.",
"     </li>",
"     <li>",
"      We rarely see rejection using the steroid protocol discussed above. In our experience, shorter tapering protocols have been associated with higher rates of rejection, including steroid-resistant rejection.",
"     </li>",
"     <li>",
"      The steroid-free regimens use expensive drugs that are not always available. Daclizumab is no longer manufactured. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Basiliximab and daclizumab'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Aggressive immunosuppression may have late consequences such as post-transplant lymphoproliferative disease (PTLD).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CALCINEURIN INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early challenges to successful liver transplantation included surgical technique, organ preservation, and immunosuppression. As surgical technique improved, the need for better immunosuppression became more obvious. A report published in 1980 described one-year survival of only 26 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/19\">",
"     19",
"    </a>",
"    ]. The introduction of the calcineurin inhibitor (CNI)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    A the following year marked a turning point in liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    , a peptide derived from the fungus Cylindrocarpon lucidum, is a potent immunosuppressive agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/22\">",
"     22",
"    </a>",
"    ]. It inhibits T-cell activation by binding intracellular cyclophilin, thus reducing calcineurin activation. Without calcineurin, the nuclear factor of activated T-cells (NFAT) does not translocate to the nucleus, and IL-2 production (along with a number of other genes) is shut down. The result is a markedly diminished T-cell response to class I and class II antigens, and a significant reduction in the rejection cascade.",
"   </p>",
"   <p>",
"    The impact of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    was illustrated in an early report in which one- and five-year survival rates with \"conventional\" immunosuppression (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) were 33 and 20 percent, respectively, while the survival rates with cyclosporine plus prednisone were 70 and 63 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/23\">",
"     23",
"    </a>",
"    ]. Cyclosporine subsequently became first-line therapy, and the first 1000 cases done at the University of Pittsburgh were described in a report in 1988 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    was initially formulated as Sandimmune, a corn oil based preparation with inconsistent absorption, especially in the absence of bile flow. Accurate dosing was difficult and serum drug levels varied with meals. In addition, any change in bile flow (eg, with rejection episodes or biliary complications) caused a change in cyclosporine absorption. This is clearly a problem after liver transplantation, so the nonaqueous, microemulsified version (Neoral) has become the preferred formulation.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    can be administered intravenously, although it is usually given orally as a tablet or an oral suspension (",
"    <a class=\"graphic graphic_table graphicRef74498 \" href=\"mobipreview.htm?7/22/7532\">",
"     table 3",
"    </a>",
"    ). The intravenous dose is about 30 percent of the oral dose because of improved bioavailability, and because it is given as a continuous infusion. All of the comments below regarding oral administration are based on the Neoral formulation of cyclosporine.",
"   </p>",
"   <p>",
"    After oral administration,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is variably absorbed in the jejunum and enters the lymphatic system. Peak blood levels are achieved in two to four hours, and the drug is widely distributed with highest concentrations in adipose, pancreatic, adrenal, renal, and hepatic tissues. The average half life is 15 hours, but ranges widely (10 to 40 hours). Cyclosporine is cleared in the bile after extensive metabolism in the liver by CYP 3A4. The metabolites have little immunosuppressive activity. CYP 3A4 activity (and, therefore, blood cyclosporine levels) depends upon genetic and environmental factors including gene polymorphisms, graft function, hepatitis C virus (HCV) replication, and certain foods and drugs (",
"    <a class=\"graphic graphic_table graphicRef81998 \" href=\"mobipreview.htm?14/44/15042\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    levels should be monitored frequently in the peritransplant period (typically daily), with decreasing frequency as graft function stabilizes and rejection becomes less of a threat. Patients who are stable can be monitored monthly, but levels should be checked more frequently if they develop an acute illness or start taking a potentially interfering drug. Several drugs commonly affect CNI levels. The goal therapeutic level of cyclosporine is usually 200 to 250",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in the first three months after transplantation, but is typically tapered to 80 to 120",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    by 12 months.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    levels should be monitored closely, and patients should be monitored for renal toxicity, hypertension, hyperkalemia, and hypomagnesemia. Potassium-sparing diuretics and potentially nephrotoxic drugs should be avoided if possible. Neurological toxicity may include altered mental status, polyneuropathy, dysarthria, myoclonus, seizures, hallucinations, and cortical blindness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/25\">",
"     25",
"    </a>",
"    ]. Other common problems include hyperlipidemia, gingival hyperplasia, and hirsutism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an update on liver transplantation in 1988, the University of Pittsburgh group reported that phase 1 trials of FK506 (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ) had recently begun [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/26\">",
"     26",
"    </a>",
"    ]. A year later, the same group described use of FK506 as salvage therapy in patients who had failed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/27\">",
"     27",
"    </a>",
"    ]. Within about five years, tacrolimus would overtake cyclosporine as the mainstay in liver transplantation.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    (Prograf) is a macrolide compound originally isolated from Streptomyces tsukubaensis. It inhibits IL-2 and interferon-gamma production, and is 100 times more potent than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . Oral bioavailability is variable (5 to 67 percent), and an oral dose of 0.15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    results in a peak concentration of 0.4 to 3.7",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    Like cyclosporine, tacrolimus is metabolized in the liver via CYP 3A4 and is not removed by dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cyclosporine versus tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;By the mid-1990s, most centers agreed that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    was associated with superior graft and patient survival. A criticism of the early studies was their use of oil based",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , raising the question of bioavailability versus efficacy. A landmark study greatly influenced thinking on the subject [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/28\">",
"     28",
"    </a>",
"    ]. The authors compared the efficacy of tacrolimus versus microemulsified cyclosporine in 606 patients undergoing first orthotopic liver transplant using a composite primary endpoint of death, retransplantation, or \"treatment failure for immunological reasons (TFIR)\". The study was an open label, randomized design, and all patients received concomitant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . TFIR was defined as biopsy-proven rejection requiring a change from protocol immunosuppression including more than one cycle of increased steroid or any increased immunosuppression, including antilymphocyte preparation or investigational drug. The justification for using TFIR as an endpoint was to avoid the distorting effect of tacrolimus rescue in patients who were failing cyclosporine therapy. The groups were well matched for diagnosis, age, gender, blood group, cold ischemia time, and intraoperative blood use.",
"   </p>",
"   <p>",
"    Both treatment regimens were effective, but",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    was superior with regard to the composite endpoint and for patient and graft survival (",
"    <a class=\"graphic graphic_figure graphicRef63344 \" href=\"mobipreview.htm?14/58/15279\">",
"     figure 3",
"    </a>",
"    ). In addition, more patients in the tacrolimus group survived without an episode of significant rejection.",
"   </p>",
"   <p>",
"    The results of the study were updated with a two-year extension of the randomization protocol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/29\">",
"     29",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    remained superior for the composite endpoint (RR 0.79; 95% CI 0.60-0.95), although the individual endpoints of freedom from death or retransplantation were no longer statistically significant. Significantly more patients randomized to tacrolimus were alive with their original graft and on their assigned medication compared with the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    group (62 versus 42 percent). Six patients were switched from tacrolimus to cyclosporine, while 17 were switched from cyclosporine to tacrolimus (five for graft rejection not meeting endpoint criteria).",
"   </p>",
"   <p>",
"    Multiple subsequent studies have been performed; the superiority of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    was confirmed in a meta-analysis of 16 randomized clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Tacrolimus was superior when analyzed for survival, graft loss, acute rejection, and steroid-resistant rejection in the first year (",
"    <a class=\"graphic graphic_table graphicRef77871 \" href=\"mobipreview.htm?20/7/20603\">",
"     table 5",
"    </a>",
"    ). The incidence of lymphoproliferative disease was similar for the two groups, and de novo diabetes mellitus was more common in the tacrolimus group. More patients stopped cyclosporine than tacrolimus. The authors estimated that treating 100 patients with tacrolimus versus cyclosporine would avoid rejection, steroid-resistant rejection, graft loss, and death in nine, seven, five, and two patients, respectively, but that four additional patients would develop diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Tacrolimus dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    dosing should be individualized. We usually start with a low dose (0.5 to 1 mg every 12 hours) on postoperative day one, and aim for a level of 7 to 10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    by the end of the first week. We use lower dosing, often with the addition of an auxiliary agent like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil or a monoclonal antibody in patients with preoperative renal impairment. It is important to attain adequate tacrolimus levels quickly. In a study of 493 liver transplantation recipients who were treated with tacrolimus as their primary immunosuppression, patients with trough tacrolimus levels &gt;7",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    at the time of a protocol liver biopsy (mean 6 days after transplantation) had lower rates of moderate or severe rejection compared with those who had lower levels (24 versus 41 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/32\">",
"     32",
"    </a>",
"    ]. In addition, patients with mean levels between 7 and 10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    within 15 days after liver transplantation had lower rates of graft loss during follow-up compared with patients who had trough levels &lt;7",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or 10 to 15",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (relative risks of 2.32 and 2.17, respectively). These findings suggest that in the early post-transplantation period, a tacrolimus level between 7 and 10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    is associated with improved outcomes. However, it must be kept in mind that because the study was not a randomized trial, it is at risk for bias and confounding.",
"   </p>",
"   <p>",
"    A level of 6",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    is satisfactory after six months, and maintenance at a level of 4 to 6",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    is common beyond one year. We tend to aim for slightly higher levels in patients who are transplanted for autoimmune liver diseases, including primary biliary cirrhosis and primary sclerosing cholangitis. Patients transplanted for alcoholic liver disease or hemochromatosis usually tolerate low levels of CNIs after their initial recovery. With improved survival, our goal is to use as little immunosuppression as possible to minimize the known long-term complications of these drugs, including renal insufficiency and lymphoproliferative disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Calcineurin inhibitors and renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;CNI-induced renal failure is a serious problem after orthotopic liver transplant (OLT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/33\">",
"     33",
"    </a>",
"    ]. The problem has been exacerbated by the switch to a MELD-based organ allocation system, which is weighted towards higher serum creatinine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=see_link\">",
"     \"Model for End-stage Liver Disease (MELD)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of strategies, including switching to mammalian target of rapamycin (mTOR) inhibitors or using alternative supplemental immunosuppressive agents have been tried. A retrospective analysis of patients who received either dual therapy with a CNI and a steroid (n = 3884) or triple therapy with a CNI, steroid, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF, n = 4946 patients) found that triple therapy was associated with a 6 percent lower adjusted risk of progressive renal disease as well as lower risk of death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/34\">",
"     34",
"    </a>",
"    ]. Progressive renal disease was defined as time to a 25 percent decline in estimated glomerular filtration rate (eGFR) based on the Modification of Diet in Renal Disease (MDRD) study formula. The authors hypothesized that MMF improved renal function by lowering CNI dosing and via a direct nephroprotective effect.",
"   </p>",
"   <p>",
"    A prospective, multicenter trial compared standard dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    to low dose and delayed tacrolimus with the primary endpoint of a change in eGFR (Cockroft-Gault formula) at 52 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients were divided into three groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Group A (n = 183): Standard dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      (target trough &gt;10",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      and steroids",
"     </li>",
"     <li>",
"      Group B (n = 70): MMF 2",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      (target trough 8",
"      <span class=\"nowrap\">",
"       ng/mL),",
"      </span>",
"      and steroids",
"     </li>",
"     <li>",
"      Group C (n = 172): Daclizumab induction, MMF, reduced-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      delayed until the fifth day post-transplant, and steroids",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The eGFR decreased by 23.6, 21.2, and 13.6",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    in groups A, B, and C, respectively (A versus C, p = 0.012; A versus B, p = 0.199).",
"   </p>",
"   <p>",
"    Hemodialysis was required more frequently in group A compared with group C (10 versus 4 percent). Biopsy-proven acute rejection rates were 28, 29, and 19 percent, respectively. Patient and graft survival were similar among the groups. This study suggests that the kidney is particularly vulnerable to injury in the immediate post-OLT period. Delayed CNI dosing reduced, but did not eliminate, renal injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Calcineurin inhibitors and HCV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selection of a specific calcineurin inhibitor in liver transplant recipients with HCV remains unclear. A theoretical advantage of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is that it inhibits HCV replication in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Whether this translates into a clinical benefit has not been established since studies have produced disparate results as illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective, multicenter trial in HCV liver transplant recipients compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      over 12 months from the time of transplant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/38\">",
"       38",
"      </a>",
"      ]. No difference in histologically proven recurrence was seen, and higher HCV RNA levels were seen in the cyclosporine arm.",
"     </li>",
"     <li>",
"      By contrast, a single center retrospective study showed significantly longer graft survival in HCV liver transplant recipients who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      over 60 months, although the cyclosporine arm was considerably smaller (n = 15) than the tacrolimus arm (n = 89) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The controversy was addressed by a large meta-analysis comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in five randomized controlled trials that studied the outcomes of hepatitis C recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/40\">",
"     40",
"    </a>",
"    ]. These studies were all of at least one-year duration and included data on mortality, graft loss, and acute rejection, but were limited in other endpoints (eg, fibrosis) related to HCV. There were no significant differences in patient mortality, graft survival, or biopsy-proven rejection. Fibrosing cholestatic hepatitis, a severe form of recurrent HCV, was found in only five patients in the tacrolimus arm and two in the cyclosporine arm.",
"   </p>",
"   <p>",
"    The mixed data described above have left the choice of CNI open-ended, but",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is now used less frequently in liver transplant recipients. Careful monitoring of CNI levels may be more important than the actual drug selected. HCV replication decreases CNI metabolism, resulting in higher drug levels despite dose reductions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/41\">",
"     41",
"    </a>",
"    ]. The higher levels may be due to downregulation of CYP 3A4, resulting in impaired clearance of the drug. As a result, careful monitoring of CNI levels in HCV transplant recipients is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Summary on the role of calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    are potent immunosuppressive agents. Their availability has allowed us to shift our focus from acute cellular rejection and short-term posttransplant survival to long-term management of complications. They have similar adverse effects including nephrotoxicity, neurotoxicity, and electrolyte abnormalities, and both can be monitored with drug levels.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    is superior in terms of preventing acute rejection, steroid-resistant rejection, graft loss, and postoperative death. These findings have made tacrolimus first line therapy in most liver transplant centers despite its higher association with posttransplant diabetes mellitus. Diabetes is a significant concern since it will probably contribute to the progressive renal failure that may be seen in long-term survivors.",
"   </p>",
"   <p>",
"    Current thinking is that significant immunosuppression is needed in the immediate posttransplant period. Beyond this period, the complications of excessive immunosuppression outweigh the ever decreasing risk of organ rejection. With careful monitoring, low doses of immunosuppression are usually well tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN (MTOR)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Sirolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    (Rapamune), a macrolide antibiotic produced by Streptomyces hygroscopicus, is a potent immunosuppressive agent approved by Food and Drug Administration for renal transplantation in 1999 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/42\">",
"     42",
"    </a>",
"    ]. It is structurally similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and binds the same target (FK-binding protein), but does not inhibit calcineurin. Instead, it blocks the transduction signal from the IL-2 receptor, thus inhibiting T and B cell proliferation. Its advantage over the calcineurin inhibitors (CNIs) is its freedom from nephrotoxicity and neurotoxicity. However, side effects of sirolimus have relegated it to the status of an important second line drug. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Its effectiveness was illustrated in an early report of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    use in 15 patients undergoing liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/43\">",
"     43",
"    </a>",
"    ]. Sirolimus was used as a single agent or as part of dual (sirolimus and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ) or triple therapy (sirolimus, cyclosporine, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    ). Rejection was seen more commonly with monotherapy, rarely with dual therapy, and not at all with triple therapy. In addition, all patients were on sirolimus monotherapy by three months. Only 3 of the 15 patients discontinued sirolimus: one for hyperlipidemia, one for taste perversion, and one for Pneumocystis pneumonia.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    binds its target (FK-binding protein) with higher affinity than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , the two drugs act synergistically rather than competitively to prevent rejection. This led to speculation that a low dose combination strategy might reduce the incidence of tacrolimus-associated problems. In a study of 56 patients on this combination, patient and graft survival at 23 months were 93 and 91 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/44\">",
"     44",
"    </a>",
"    ]. One case of hepatic artery thrombosis was observed in this series.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    may be especially useful as a substitute in cases of CNI intolerance (primarily renal failure and neurotoxicity) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. However, its benefits in renal failure remain unsettled. While retrospective analyses did not show improved renal function in patients switched to sirolimus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/48-50\">",
"     48-50",
"    </a>",
"    ], a small randomized controlled trial did show improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/47\">",
"     47",
"    </a>",
"    ]. In the randomized trial, transplant recipients with underlying renal disease were switched to sirolimus at least six months after liver transplant. The glomerular filtration rate improved within three months. However, long-term outcomes were not reported and two patients in the sirolimus arm developed acute rejection.",
"   </p>",
"   <p>",
"    A retrospective analysis showed no benefit for renal function when patients with chronic renal insufficiency were switched from CNIs to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/50\">",
"     50",
"    </a>",
"    ]. This study suggests that renal dysfunction from CNIs becomes irreversible at some point, and highlights the importance of CNI optimization. Similarly, another study showed that early conversion (less than 90 days) to sirolimus was associated with improved renal function, while late conversion was of limited benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review that included 11 studies found a small (3.4",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    nonsignificant increase in glomerular filtration rate after one year of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    use in patients who received sirolimus as primary immunosuppression due to renal insufficiency or who were switched to sirolimus from another regimen due to nephrotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/52\">",
"     52",
"    </a>",
"    ]. However, sirolimus use was associated with higher rates of infection, rash, ulcers and discontinuation of therapy. Sirolimus was not associated with an increased risk of graft failure or death, though the data reporting for these outcomes was incomplete.",
"   </p>",
"   <p>",
"    Larger trials with longer follow-up are needed to settle the issue and to determine whether the potential improvement in renal function outweighs a possible increased risk of rejection.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    has also been proposed as a better choice for patients with hepatocellular carcinoma because of its antiproliferative activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. This benefit has yet to be proven in prospective trials. Finally, although not supported by publications, many transplant centers find that sirolimus is inadequate as monotherapy and routinely add a second agent when switching from a CNI for any reason.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    reported in the postoperative period include hepatic artery thrombosis, delayed wound healing, and incisional hernias, while chronic use has been associated with hyperlipidemia, bone marrow suppression, mouth ulcers, skin rashes, albuminuria, and pneumonia. These risks are difficult to quantify because the incidence (and even the presence) of side effects varies widely by report. As an example, one report showed that sirolimus was more likely to cause hyperlipidemia when administered with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    than with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (30 versus 6 percent for hypercholesterolemia, 33 versus 3 percent for hypertriglyceridemia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/56\">",
"     56",
"    </a>",
"    ]. Similar results in another retrospective trial suggested that the combination of sirolimus with tacrolimus is associated with minimal elevation of triglycerides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/57\">",
"     57",
"    </a>",
"    ]. These contrast with a study that reported a 49 percent incidence of hyperlipidemia in patients switched from a CNI to sirolimus monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another retrospective study compared 170 patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    as initial therapy compared with 180 historic controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/59\">",
"     59",
"    </a>",
"    ]. No significant differences in wound complications (12 versus 14 percent) or hepatic artery complications (5 versus 8 percent) were seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/59\">",
"     59",
"    </a>",
"    ]. Finally, a large retrospective study found complications that included edema, dermatitis, oral ulcers, joint pains, pleural effusions, hepatic artery thrombosis (one patient), and one wound dehiscence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/60\">",
"     60",
"    </a>",
"    ]. The results reported in the above studies have not been validated in prospective studies.",
"   </p>",
"   <p>",
"    In June 2009, the United States Food and Drug Administration issued an alert based on an unpublished study that found increased mortality in stable liver transplant patients after conversion from a CNI-based immunosuppressive regimen to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    . Whether a labeling change is required is being determined (",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm165015.htm\">",
"     www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm165015.htm",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Everolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     Everolimus",
"    </a>",
"    is a semisynthetic form of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    . Its mechanism of action is via inhibition of mammalian target of rapamycin (mTOR), similar to sirolimus. A safety trial has been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/61\">",
"     61",
"    </a>",
"    ], but the role of this drug has yet to be established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/62\">",
"     62",
"    </a>",
"    ]. Because of an increased risk of hepatic artery thrombosis in the early post-transplantation period, the US Food and Drug Administration recommends that everolimus",
"    <strong>",
"     not",
"    </strong>",
"    be used earlier than 30 days after liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective study that followed 240 patients who were converted to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    for maintenance therapy following liver transplantation found low rates of rejection among patients on everolimus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/64\">",
"     64",
"    </a>",
"    ]. The patients were followed for a mean duration of 15 months after starting everolimus. Mild or moderate biopsy-proven acute rejection developed in four patients (1.6 percent). Because of adverse events, everolimus was discontinued in 47 patients (20 percent), and the dose was decreased in 59 (25 percent). At the initiation of everolimus, 94 percent of patients were receiving a calcineurin inhibitor, but after twelve months, only 38 percent were.",
"   </p>",
"   <p>",
"    One small (n = 10) study showed potential efficacy of this",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    in liver transplant recipients who were switched to it after developing non-liver solid organ cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/65\">",
"     65",
"    </a>",
"    ]. Everolimus was associated with improved survival at 6, 12, and 24 months compared with a control group of patients who did not receive everolimus. This suggests that control of cell cycle growth through the mTOR pathway may have a dual effect on transplant immunosuppression and antitumor growth. Major limitations of this study included its small size and lack of standardization among types of solid organ cancers and treatment regimens. A study of 19 patients suggested that everolimus may be helpful in CNI-induced renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/66\">",
"     66",
"    </a>",
"    ]. Larger prospective studies are needed, but we anticipate that results with everolimus will be similar to those seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major issue with calcineurin inhibitors and mammalian target of rapamycin (mTOR) inhibitors is their extensive metabolism by the cytochrome P-450 system. This creates the potential for drug interactions and may produce drug toxicity or dangerously low levels. A knowledge of the common interfering compounds is essential and drug levels must be monitored closely when these compounds are used (",
"    <a class=\"graphic graphic_table graphicRef81998 \" href=\"mobipreview.htm?14/44/15042\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     INHIBITORS OF PURINE AND PYRIMIDINE SYNTHESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major antimetabolite drugs are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF), a purine synthesis inhibitor, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    , a pyrimidine synthesis inhibitor, though leflunomide is not currently approved for use in transplantation.",
"   </p>",
"   <p>",
"    The original drugs in this class,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (Cytoxan) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (Imuran), are rarely used in transplantation in the United States, although a multicenter study suggested that azathioprine is used routinely in the United Kingdom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/16\">",
"     16",
"    </a>",
"    ]. While MMF has become more popular than the other agents, clear evidence of superiority is lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/67\">",
"     67",
"    </a>",
"    ]. Azathioprine is sometimes substituted for MMF in women who are pregnant or of childbearing age due to increased safety experience with it in pregnancy. MMF is pregnancy class D.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil and mycophenolate sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycophenolic acid (MPA) is produced by several species of the fungus Penicillium. MPA is poorly absorbed, but two orally available prodrugs are available in the United States; the 2-morpholinoethyl ester,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF, CellCept), and mycophenolate sodium (Myfortic). Both drugs are converted to MPA and eliminated predominantly via glucuronidation and urinary excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MPA inhibits inosine monophosphate dehydrogenase (IMPDH), preventing the formation of guanosine monophosphate (GMP). Cells depleted of GMP cannot synthesize guanine triphosphate (GTP) or deoxy guanine triphosphate (d-GTP) and therefore cannot replicate. Most mammalian cells are able to maintain GMP levels through the purine salvage pathway. However, lymphocytes lack a key enzyme of the guanine salvage pathway (hypoxanthine-guanine phosphoribosyltransferase), and cannot overcome the MPA-induced block. As a result, MPA selectively inhibits the proliferation of both B and T lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reports on the use of MMF in liver transplantation began to appear in the late 1990s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. MMF does not cause neurotoxicity or nephrotoxicity, and is widely used as a calcineurin inhibitor (CNI)- or steroid-sparing agent. The most common side effects are bone marrow suppression and gastrointestinal complaints, including abdominal pain, ileus, nausea, vomiting, and oral ulceration. These symptoms are usually dose-related and improve with temporary or permanent dose reduction. Usual dosing is 1 g twice daily. Patients may tolerate the drug better if it is initially dosed at 500 mg twice daily or 500 mg four times daily. Myfortic (mycophenolic acid) is formulated as 360 mg tablets and is typically given as two tablets (720 mg) orally every 12 hours. Food may interfere with absorption of the drugs, so they should be taken one hour before or two hours after meals.",
"   </p>",
"   <p>",
"    The role of MMF is similar to that of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    in that it is used to reduce or discontinue CNI dosing in order to treat side effects. Studies suggest MMF monotherapy may be effective in certain situations long after liver transplantation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial assigned 150 patients who had received a liver transplantation and were maintained on a CNI to either continued therapy with a CNI or to MMF monotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/71\">",
"       71",
"      </a>",
"      ]. The mean time between liver transplantation and study enrollment was 4.9 years for patients assigned to continued CNI therapy, and 5.7 years for those assigned to MMF. After five years of follow-up, there were no significant differences between those who continued on a CNI and those who were switched to MMF with regard to chronic rejection or patient survival (0 verus 0 percent and 94 verus 90 percent, respectively). There was a trend toward lower acute rejection rates in the CNI group (3 versus 11 percent, p = 0.055). All patients with acute rejection were successfully treated with steroid-pulse therapy. Among patients with renal insufficiency, renal function improved in those switched to MMF. There were no significant differences between the groups with regard to malignancy rates or to adverse cardiovascular, gastrointestinal, or neurologic events.",
"     </li>",
"     <li>",
"      In a prospective open-label study, 19 patients at the University of Washington were switched from",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      to MMF with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , which was then tapered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/72\">",
"       72",
"      </a>",
"      ]. After five years, seven patients remained off cyclosporine, and six patients were on MMF monotherapy. Serum creatinine in the seven patients off cyclosporine decreased significantly (from 2.2 to 1.9",
"      <span class=\"nowrap\">",
"       mg/dL),",
"      </span>",
"      while creatinine clearance increased significantly (from 38 to 47",
"      <span class=\"nowrap\">",
"       mL/min).",
"      </span>",
"      Control of arterial hypertension also improved. MMF appeared to be well-tolerated, although six patients required dose reductions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The added immunosuppression of MMF may also allow for the early discontinuation or avoidance of steroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Glucocorticoids and HCV'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Leflunomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     Leflunomide",
"    </a>",
"    (Arava) is a member of the malonitrilamide class of agents. Its active metabolite inhibits both tyrosine phosphorylation and dihydro-orotate dehydrogenase, an enzyme necessary for de novo pyrimidine synthesis. Its potential role is similar to that of MMF, but it is not approved by the Food and Drug administration for transplantation and is not currently in use. The efficacy of leflunomide has been suggested in animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     ANTIBODY THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because T and B cells express specific antigens on their cell surfaces, antibodies to these markers can be used to deplete populations of cells. The initial concept of lymphoid depletion by thoracic duct fistula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/75\">",
"     75",
"    </a>",
"    ] gave way to the more elegant method of antithymocyte globulin preparations, now refined to include humanized antibodies and monoclonal antibodies against specific cell surface proteins such as the IL-2 receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These agents are not used routinely in liver transplantation, but have an important role in treating steroid-resistant rejection and as calcineurin inhibitor (CNI)-sparing agents in the immediate posttransplant period. Antibody therapy may also permit steroid free immunosuppression regimens if needed. We generally use antibody preparations in the rare case of steroid-resistant rejection and in situations where we wish to minimize CNI dosing, such as in patients with pretransplant renal failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/47/41718?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of acute cellular rejection in liver transplantation\", section on 'Steroid-resistant rejection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Polyclonal antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antithymocyte globulin (ATG, Thymoglobulin) and antilymphocyte globulin (ALG) are prepared by immunizing animals against mixed populations of thymocytes. The resulting preparations have antibodies to multiple T-cell antigens including CD2, CD3, CD4, and CD8. They are administered via a central line and result in profound lymphopenia by complement-mediated cell lysis and uptake of opsonized cells. Repopulation occurs within 3 to 10 days.",
"   </p>",
"   <p>",
"    Polyclonal antibodies have been used sporadically for induction or treatment of steroid-resistant rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/12,77\">",
"     12,77",
"    </a>",
"    ]. A review of the Scientific Registry of Transplant Recipient (SRTR) data over the last ten years showed that antibodies were used commonly in kidney,",
"    <span class=\"nowrap\">",
"     kidney/pancreas,",
"    </span>",
"    and intestinal transplants, but uncommonly (&lt;20 percent) in liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/78\">",
"     78",
"    </a>",
"    ]. The authors also noted a shift from muromonab-CD3 and horse ATG to rabbit ATG and anti-IL-2 receptor antagonists. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Muromonab-CD3 (OKT3)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Complications with these agents include fever, chills, rash, anemia, thrombocytopenia, serum sickness, and nephritis. Although our personal preference is to use monoclonal antibodies when necessary, some reports suggest that polyclonal antibodies are still in use in pediatric and adult patients undergoing liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Monoclonal antibodies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Muromonab-CD3 (OKT3)",
"    </span>",
"    &nbsp;&mdash;&nbsp;OKT3 (Orthoclone OKT3) was the first monoclonal antibody approved for use in solid organ transplantation. It is directed against the CD3-antigen complex on mature T-cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/81\">",
"     81",
"    </a>",
"    ]. Binding this receptor causes internalization of the receptor followed by opsonization and removal of T-cells from the circulation. It also blocks killer T-cell activity in the graft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    OKT3 was an early agent in managing steroid-resistant rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. An illustrative trial included 28 patients with steroid-resistant rejection who were randomly assigned to further steroid treatment versus OKT3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/83\">",
"     83",
"    </a>",
"    ]. In the steroid group, 3 out of 13 patients responded promptly to further methylprednisolone and the remaining ten patients were switched to OKT3 rescue after failing to respond to steroids. Of these 10 patients, nine responded to OKT3, and seven were well at 1 to 17 months follow-up. In the OKT3 group, 11 of 15 responded within 72 hours. Two patients with an inadequate response to OKT3 were rescued with steroids, one was retransplanted, and one died of sepsis following a biliary fistula.",
"   </p>",
"   <p>",
"    The standard dose of OKT3 is 5 mg IV daily for 10 to 14 days. The initial two to three doses typically cause a cytokine release syndrome characterized by fever, chills, headache, chest pain, tachycardia, dyspnea, wheezing, nausea, and vomiting. Onset is usually within an hour of the infusion, and symptoms usually resolve in four to six hours. A slower infusion rate along with pretreatment with 1 g",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    (first dose only), 650 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , and 25 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    has been recommended, but there is no agreement on a standard pretreatment protocol. Pulmonary edema should be excluded with a chest x-ray prior to infusion, and symptoms should be treated aggressively with diuretics. Asymptomatic meningitis usually responds to 100 mg hydrocortisone prior to each infusion.",
"   </p>",
"   <p>",
"    Successful OKT treatment is associated with a rapid decline in CD3-positive T-cells from approximately 60 to less than 5 percent. Failure of this decline, or a fall followed by a rapid rise indicates the appearance of blocking antibodies. A review of the literature suggested close monitoring of the absolute neutrophil count (ANC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/85\">",
"     85",
"    </a>",
"    ]. The authors recommended that patients whose ANC did not decline below 500",
"    <span class=\"nowrap\">",
"     cells/mL",
"    </span>",
"    be treated with a double dose of OKT3 to overwhelm the developing antibodies.",
"   </p>",
"   <p>",
"    The efficacy of OKT3 is tempered by concern about complications, mainly worse outcomes in patients with recurrent hepatitis C and posttransplant lymphoproliferative disorder (PTLD). The occurrence of PTLD may be higher in patients who are transplanted for HCV, although probably not as high as the 7 percent reported in one small series (57 patients with HCV, 127 without HCV) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/86\">",
"     86",
"    </a>",
"    ]. In the five patients with PTLD, four were transplanted for HCV, and all five had received OKT3 induction.",
"   </p>",
"   <p>",
"    Two large single-center series showed remarkably similar incidences of PTLD; 41 out of 1421 patients (3 percent) in a series from Dallas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/87\">",
"     87",
"    </a>",
"    ], and 37 out of 1421 patients (3 percent) in a series from the Mayo Clinic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/88\">",
"     88",
"    </a>",
"    ]. The Dallas group showed no relationship to OKT3 use or severity of rejection, but the Mayo study showed a significant correlation with OKT3 (HR = 3.6), high dose steroids (HR = 4.5), or either (HR = 3.6).",
"   </p>",
"   <p>",
"    Concern about the danger of PTLD, especially in the setting of HCV infection, was reflected in a survey of North American transplant centers conducted in 1998 and repeated in 2003; a general trend toward reduced use of OKT3 in HCV-infected patients was observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Basiliximab and daclizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"     Basiliximab",
"    </a>",
"    (Simulect) and daclizumab (Zenapax) are humanized monoclonal antibodies against the interleukin (IL)-2 receptor. Blockade of the IL-2 receptor prevents T-cell proliferation. The chimeric structure makes both preparations less immunogenic than OKT3, and they have longer half-lives and are better tolerated. Basiliximab, for example, has an elimination half-life of 4.1 &plusmn; 2.1 days, and complete saturation of interleukin-2 receptor alpha-chain was maintained as long as serum concentrations exceeded 0.1",
"    <span class=\"nowrap\">",
"     microgram/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/90\">",
"     90",
"    </a>",
"    ]. The mean duration of receptor saturation was 23",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    7 days after transplantation (range of 13 to 41 days). The half-life may be decreased by the presence of bleeding or ascites.",
"   </p>",
"   <p>",
"    Similar efficacy has been demonstrated with daclizumab dosed at 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    on post-orthotopic liver transplant (OLT) days one and three, and 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    on day eight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/91\">",
"     91",
"    </a>",
"    ]. CD25 suppression was confirmed through day 30, and maximal effects were noted with a daclizumab concentration of at least 5",
"    <span class=\"nowrap\">",
"     micrograms/mL.",
"    </span>",
"    Similarly, a nonrandomized study of daclizumab 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    before engraftment and 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    on day five post-OLT resulted in a much lower rejection rate in the first six months (18 versus 40 percent), marked improvement in renal function, and no increase in CMV or infectious complications when compared with a control group treated with standard immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/92\">",
"     92",
"    </a>",
"    ]. Daclizumab was removed from the market in 2009 for commercial reasons; no clinical issues were identified, and we continue to believe that daclizumab is an excellent drug.",
"   </p>",
"   <p>",
"    Antibodies can be used to reduce CNI use in patients with pre-OLT renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/93\">",
"     93",
"    </a>",
"    ] or to minimize steroid use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/18,94\">",
"     18,94",
"    </a>",
"    ]. In one report,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"     basiliximab",
"    </a>",
"    controlled steroid-resistant rejection after OLT in five out of seven children age 8 to 23 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Few controlled trials have compared contemporary immunosuppressive regimens involving these agents. One randomized multicenter study compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    plus steroids (T+S; 347 patients) to a steroid-free tacrolimus plus daclizumab group (T+D; 351 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/96\">",
"     96",
"    </a>",
"    ]. The incidence of biopsy-confirmed glucocorticoid-resistant acute rejection was higher in the T+S group (6 versus 3 percent), although graft and patient survival were comparable. The overall adverse event profiles were similar, but the incidences of diabetes mellitus (15 versus 6 percent) and CMV infection (12 versus 5 percent) were significantly higher in the T+S group. Mean cholesterol levels increased by 16 percent in the T+S group, but were unchanged in the T+D group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     EXPERIMENTAL AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Belatacept (LEA29Y)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/41/43669?source=see_link\">",
"     Belatacept",
"    </a>",
"    is a high affinity fusion protein that binds",
"    <span class=\"nowrap\">",
"     CD80/86",
"    </span>",
"    on antigen-presenting cells (APCs). This prevents binding of",
"    <span class=\"nowrap\">",
"     CD80/86",
"    </span>",
"    to CD28 on the T-cell (signal II in Figure 1) (",
"    <a class=\"graphic graphic_figure graphicRef54486 \" href=\"mobipreview.htm?26/2/26658\">",
"     figure 1",
"    </a>",
"    ), and blocks the costimulatory pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/97\">",
"     97",
"    </a>",
"    ]. The drug is given as a monthly infusion and may permit immunosuppression without nephrotoxicity. Several reports confirm its effectiveness in renal transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/98-100\">",
"     98-100",
"    </a>",
"    ], but an increased rate of post-transplant lymphoproliferative disorder, especially involving the central nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/101\">",
"     101",
"    </a>",
"    ], has confined its use to Epstein-Barr virus-positive recipients. We are unaware of belatacept use in liver transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Efalizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is a humanized monoclonal antibody against leukocyte function-associated antigen-1 (LFA-1; CD11a). LFA-1 plays multiple roles in rejection, including cell migration, cell adhesion, and stabilization of the APC-T-cell complex. An open label trial of efalizumab with lower doses of standard immunosuppression suggested that the drug was effective, but associated with an 11 percent incidence of PTLD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/98\">",
"     98",
"    </a>",
"    ]. The role of this potent compound in liver transplantation has yet to be determined.",
"   </p>",
"   <p>",
"    A few other agents, including alefacept and a Janus tyrosine kinase 3 inhibitor, are in early testing in renal transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15476300\">",
"    <span class=\"h2\">",
"     Alemtuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    is a humanized monoclonal, complement-fixing, anti-CD52 antibody. CD52 is expressed on the surface of B-lymphocytes, T-lymphocytes, macrophages, monocytes, and eosinophils. Through compliment activation, alemtuzumab leads to profound lymphocyte depletion. It is approved by the Food and Drug Administration for the treatment of chronic B-cell lymphocytic leukemia, but it has also been used for immunosuppression following solid organ transplantation. In liver transplantation, alemtuzumab has been proposed as a method to decrease steroid and calcineurin inhibitor use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/13\">",
"     13",
"    </a>",
"    ]. However, concern about profound immunosuppression with attendant infectious complications and PTLD have reduced enthusiasm for alemtuzumab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/103-105\">",
"     103-105",
"    </a>",
"    ], although one review supports further studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/12/30922/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute cellular rejection, once the major impediment to patient survival, has become a relatively minor issue in contemporary liver transplantation.",
"     </li>",
"     <li>",
"      The focus is now on the long-term consequences of immunosuppression, including renal disease, diabetes, hyperlipidemia, and malignancy.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       Tacrolimus",
"      </a>",
"      remains the mainstay of immunosuppression in many centers. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Tacrolimus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal disease prior to transplant is easier to manage with the use of antibody preparations or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil (MMF) along with delayed calcineurin inhibitors (CNIs). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Antibody therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Calcineurin inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Slowly worsening renal disease in the late post-orthotopic liver transplant period can be managed by reducing the CNI dose, with the addition of MMF, or by switching to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Sirolimus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Randomized trials are difficult in a rapidly moving field; new and better compounds have always become available before enrollment could be completed. With survival rates now reported above 90 percent, improvements will be incremental, and long-term studies will be necessary.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/1\">",
"      A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. N Engl J Med 1994; 331:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/2\">",
"      Vacca A, Felli MP, Farina AR, et al. Glucocorticoid receptor-mediated suppression of the interleukin 2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements. J Exp Med 1992; 175:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/3\">",
"      Ray A, LaForge KS, Sehgal PB. On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion. Mol Cell Biol 1990; 10:5736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/4\">",
"      Verhoef CM, van Roon JA, Vianen ME, et al. The immune suppressive effect of dexamethasone in rheumatoid arthritis is accompanied by upregulation of interleukin 10 and by differential changes in interferon gamma and interleukin 4 production. Ann Rheum Dis 1999; 58:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/5\">",
"      Toniutto P, Fabris C, Fumolo E, et al. Prevalence and risk factors for delayed adrenal insufficiency after liver transplantation. Liver Transpl 2008; 14:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/6\">",
"      Henry SD, Metselaar HJ, Van Dijck J, et al. Impact of steroids on hepatitis C virus replication in vivo and in vitro. Ann N Y Acad Sci 2007; 1110:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/7\">",
"      Kim SS, Peng LF, Lin W, et al. A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication. Gastroenterology 2007; 132:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/8\">",
"      Lake JR. Immunosuppression and outcomes of patients transplanted for hepatitis C. J Hepatol 2006; 44:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/9\">",
"      Klintmalm GB, Washburn WK, Rudich SM, et al. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007; 13:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/10\">",
"      Klintmalm GB, Davis GL, Teperman L, et al. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl 2011; 17:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/11\">",
"      Llad&oacute; L, Xiol X, Figueras J, et al. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. J Hepatol 2006; 44:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/12\">",
"      Eason JD, Nair S, Cohen AJ, et al. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003; 75:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/13\">",
"      Marcos A, Eghtesad B, Fung JJ, et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2004; 78:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/14\">",
"      Berenguer M, Aguilera V, Prieto M, et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006; 44:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/15\">",
"      Llad&oacute; L, Fabregat J, Castellote J, et al. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transpl 2008; 14:1752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/16\">",
"      Manousou P, Samonakis D, Cholongitas E, et al. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl 2009; 15:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/17\">",
"      Sgourakis G, Radtke A, Fouzas I, et al. Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. Transpl Int 2009; 22:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/18\">",
"      Washburn K, Speeg KV, Esterl R, et al. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. Transplantation 2001; 72:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/19\">",
"      Starzl TE, Koep L, Porter KA, et al. Decline in survival after liver transplantation. Arch Surg 1980; 115:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/20\">",
"      Starzl TE, Klintmalm GB, Porter KA, et al. Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med 1981; 305:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/21\">",
"      Calne RY. Liver transplantation. Ann Clin Res 1981; 13:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/22\">",
"      Borel JF, Feurer C, Gubler HU, St&auml;helin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976; 6:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/23\">",
"      Gordon RD, Shaw BW Jr, Iwatsuki S, et al. Indications for liver transplantation in the cyclosporine era. Surg Clin North Am 1986; 66:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/24\">",
"      Iwatsuki S, Starzl TE, Todo S, et al. Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc 1988; 20:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/25\">",
"      Stracciari A, Guarino M. Neuropsychiatric complications of liver transplantation. Metab Brain Dis 2001; 16:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/26\">",
"      Gordon RD, Starzl TE. Changing perspectives on liver transplantation in 1988. Clin Transpl 1988; :5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/27\">",
"      Starzl TE, Todo S, Fung J, et al. FK 506 for liver, kidney, and pancreas transplantation. Lancet 1989; 2:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/28\">",
"      O'Grady JG, Burroughs A, Hardy P, et al. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet 2002; 360:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/29\">",
"      O'Grady JG, Hardy P, Burroughs AK, et al. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. Am J Transplant 2007; 7:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/30\">",
"      McAlister VC, Haddad E, Renouf E, et al. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006; 6:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/31\">",
"      Haddad EM, McAlister VC, Renouf E, et al. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006; :CD005161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/32\">",
"      Rodr&iacute;guez-Per&aacute;lvarez M, Germani G, Papastergiou V, et al. Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome. J Hepatol 2013; 58:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/33\">",
"      Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/34\">",
"      Lake J, Patel D, David K, et al. The association between MMF and risk of progressive renal dysfunction and death in adult liver transplant recipients with HCV. Clin Transplant 2009; 23:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/35\">",
"      Neuberger JM, Mamelok RD, Neuhaus P, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant 2009; 9:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/36\">",
"      Nakagawa M, Sakamoto N, Enomoto N, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004; 313:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/37\">",
"      Firpi RJ, Zhu H, Morelli G, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006; 12:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/38\">",
"      Martin P, Busuttil RW, Goldstein RM, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl 2004; 10:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/39\">",
"      Rayhill SC, Barbeito R, Katz D, et al. A cyclosporine-based immunosuppressive regimen may be better than tacrolimus for long-term liver allograft survival in recipients transplanted for hepatitis C. Transplant Proc 2006; 38:3625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/40\">",
"      Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007; 13:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/41\">",
"      Oo YH, Dudley T, Nightingale P, et al. Tacrolimus and cyclosporin doses and blood levels in hepatitis C and alcoholic liver disease patients after liver transplantation. Liver Transpl 2008; 14:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/42\">",
"      Hirose R, Vincenti F. Review of transplantation--1999. Clin Transpl 1999; :295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/43\">",
"      Watson CJ, Friend PJ, Jamieson NV, et al. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 1999; 67:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/44\">",
"      McAlister VC, Peltekian KM, Malatjalian DA, et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 2001; 7:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/45\">",
"      Neff GW, Montalbano M, Tzakis AG. Ten years of sirolimus therapy in orthotopic liver transplant recipients. Transplant Proc 2003; 35:209S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/46\">",
"      Beckebaum S, Cicinnati V, Brokalaki E, et al. CNI-sparing regimens within the liver transplant setting: experiences of a single center. Clin Transpl 2004; :215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/47\">",
"      Watson CJ, Gimson AE, Alexander GJ, et al. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2007; 13:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/48\">",
"      Campbell MS, Rai J, Kozin E, et al. Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation. Clin Transplant 2007; 21:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/49\">",
"      Shenoy S, Hardinger KL, Crippin J, et al. Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial. Transplantation 2007; 83:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/50\">",
"      DuBay D, Smith RJ, Qiu KG, et al. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens. Liver Transpl 2008; 14:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/51\">",
"      Rogers CC, Johnson SR, Mandelbrot DA, et al. Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients. Clin Transplant 2009; 23:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/52\">",
"      Asrani SK, Leise MD, West CP, et al. Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis. Hepatology 2010; 52:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/53\">",
"      Kneteman NM, Oberholzer J, Al Saghier M, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004; 10:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/54\">",
"      Toso C, Meeberg GA, Bigam DL, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007; 83:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/55\">",
"      Zimmerman MA, Trotter JF, Wachs M, et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008; 14:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/56\">",
"      Trotter JF, Wachs ME, Trouillot TE, et al. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transpl 2001; 7:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/57\">",
"      Kniepeiss D, Iberer F, Schaffellner S, et al. Dyslipidemia during sirolimus therapy in patients after liver transplantation. Clin Transplant 2004; 18:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/58\">",
"      Morard I, Dumortier J, Spahr L, et al. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. Liver Transpl 2007; 13:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/59\">",
"      Dunkelberg JC, Trotter JF, Wachs M, et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl 2003; 9:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/60\">",
"      Montalbano M, Neff GW, Yamashiki N, et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation 2004; 78:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/61\">",
"      Levy G, Schmidli H, Punch J, et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 2006; 12:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/62\">",
"      Everson GT. Everolimus and mTOR inhibitors in liver transplantation: opening the \"box\". Liver Transpl 2006; 12:1571.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm303659.htm (Accessed on March 12, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/64\">",
"      Saliba F, Dharancy S, Lorho R, et al. Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis. Liver Transpl 2011; 17:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/65\">",
"      Gomez-Camarero J, Salcedo M, Rincon D, et al. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation 2007; 84:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/66\">",
"      Castroagud&iacute;n JF, Molina E, Romero R, et al. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Liver Transpl 2009; 15:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/67\">",
"      Germani G, Pleguezuelo M, Villamil F, et al. Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil. Am J Transplant 2009; 9:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/68\">",
"      Hood KA, Zarembski DG. Mycophenolate mofetil: a unique immunosuppressive agent. Am J Health Syst Pharm 1997; 54:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/69\">",
"      Stegall MD, Wachs ME, Everson G, et al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation 1997; 64:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/70\">",
"      Klupp J, Bechstein WO, Platz KP, et al. Mycophenolate mofetil added to immunosuppression after liver transplantation--first results. Transpl Int 1997; 10:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/71\">",
"      Schmeding M, Kiessling A, Neuhaus R, et al. Mycophenolate mofetil monotherapy in liver transplantation: 5-year follow-up of a prospective randomized trial. Transplantation 2011; 92:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/72\">",
"      Hebert MF, Ascher NL, Lake JR, et al. Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. Transplantation 1999; 67:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/73\">",
"      O'Grady JG. Corticosteroid-free strategies in liver transplantation. Drugs 2006; 66:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/74\">",
"      Chong AS, Huang W, Liu W, et al. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. Transplantation 1999; 68:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/75\">",
"      Starzl TE, Koep LJ, Halgrimson CG, et al. Liver transplantation--1978. Transplant Proc 1979; 11:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/76\">",
"      Briggs JD. A critical review of immunosuppressive therapy. Immunol Lett 1991; 29:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/77\">",
"      Eason JD, Loss GE, Blazek J, et al. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial. Liver Transpl 2001; 7:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/78\">",
"      Shapiro R, Young JB, Milford EL, et al. Immunosuppression: evolution in practice and trends, 1993-2003. Am J Transplant 2005; 5:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/79\">",
"      Shah A, Agarwal A, Mangus R, et al. Induction immunosuppression with rabbit antithymocyte globulin in pediatric liver transplantation. Liver Transpl 2006; 12:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/80\">",
"      Varo E, L&oacute;pez A, Rivero C. Initial immunosuppression in liver transplant recipients with impaired renal function. Transplant Proc 2005; 37:3909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/81\">",
"      Cosimi AB. Clinical development of Orthoclone OKT3. Transplant Proc 1987; 19:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/82\">",
"      Goldstein G, Kremer AB, Barnes L, Hirsch RL. OKT3 monoclonal antibody reversal of renal and hepatic rejection in pediatric patients. J Pediatr 1987; 111:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/83\">",
"      Cosimi AB, Cho SI, Delmonico FL, et al. A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection. Transplantation 1987; 43:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/84\">",
"      Busuttil RW, Colonna JO 2nd, Hiatt JR, et al. The first 100 liver transplants at UCLA. Ann Surg 1987; 206:387.",
"     </a>",
"    </li>",
"    <li>",
"     Chinnakotla S, Klintmalm G. Induction and maintenance of immunosuppression. In: Transplantation of the Liver, Busuttil R, Klintmalm G (Eds), Elsevier Saunders, Philadelphia 2005. Vol 1213.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/86\">",
"      McLaughlin K, Wajstaub S, Marotta P, et al. Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C. Liver Transpl 2000; 6:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/87\">",
"      Sanchez EQ, Marubashi S, Jung G, et al. De novo tumors after liver transplantation: a single-institution experience. Liver Transpl 2002; 8:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/88\">",
"      Kremers WK, Devarbhavi HC, Wiesner RH, et al. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant 2006; 6:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/89\">",
"      Khalili M, Vardanian AJ, Hamerski CM, et al. Management of hepatitis C-infected liver transplant recipients at large North American centres: changes in recent years. Clin Transplant 2006; 20:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/90\">",
"      Kovarik J, Breidenbach T, Gerbeau C, et al. Disposition and immunodynamics of basiliximab in liver allograft recipients. Clin Pharmacol Ther 1998; 64:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/91\">",
"      Washburn WK, Teperman LW, Heffron TG, et al. A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: a pharmacokinetic and pharmacodynamic study. Liver Transpl 2006; 12:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/92\">",
"      Eckhoff DE, McGuire B, Sellers M, et al. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. Transplantation 2000; 69:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/93\">",
"      Emre S, Gondolesi G, Polat K, et al. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2001; 7:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/94\">",
"      Liu CL, Fan ST, Lo CM, et al. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl 2004; 10:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/95\">",
"      Aw MM, Taylor RM, Verma A, et al. Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience. Transplantation 2003; 75:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/96\">",
"      Boillot O, Mayer DA, Boudjema K, et al. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transpl 2005; 11:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/97\">",
"      Pondrom S. The AJT report: News and issues that affect organ and tissue transplantation. Belatacept results promising...with some caveats. Am J Transplant 2009; 9:2445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/98\">",
"      Vincenti F, Mendez R, Pescovitz M, et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 2007; 7:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/99\">",
"      Larsen CP, Griny&oacute; J, Medina-Pestana J, et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010; 90:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/100\">",
"      Rostaing L, Massari P, Garcia VD, et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol 2011; 6:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/101\">",
"      Griny&oacute; J, Charpentier B, Pestana JM, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 2010; 90:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/102\">",
"      Pillai AA, Levitsky J. Overview of immunosuppression in liver transplantation. World J Gastroenterol 2009; 15:4225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/103\">",
"      Anoop P, Wotherspoon A, Matutes E. Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemia. Br J Haematol 2010; 148:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/104\">",
"      Alcaide ML, Abbo L, Pano JR, et al. Herpes zoster infection after liver transplantation in patients receiving induction therapy with alemtuzumab. Clin Transplant 2008; 22:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/105\">",
"      Silveira FP, Husain S, Kwak EJ, et al. Cryptococcosis in liver and kidney transplant recipients receiving anti-thymocyte globulin or alemtuzumab. Transpl Infect Dis 2007; 9:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/12/30922/abstract/106\">",
"      Dhesi S, Boland B, Colquhoun S. Alemtuzumab and liver transplantation: a review. Curr Opin Organ Transplant 2009; 14:245.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4586 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-5849588C53-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_12_30922=[""].join("\n");
var outline_f30_12_30922=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMMUNOBIOLOGY OF ACUTE REJECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Signal I: Alloantigen recognition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Signal II: Lymphocyte activation (costimulation)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Signal III: Clonal expansion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Glucocorticoids and HCV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CALCINEURIN INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cyclosporine versus tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Tacrolimus dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Calcineurin inhibitors and renal failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Calcineurin inhibitors and HCV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Summary on the role of calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN (MTOR)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Sirolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Everolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      INHIBITORS OF PURINE AND PYRIMIDINE SYNTHESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Mycophenolate mofetil and mycophenolate sodium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Leflunomide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ANTIBODY THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Polyclonal antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Monoclonal antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Muromonab-CD3 (OKT3)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Basiliximab and daclizumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      EXPERIMENTAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Belatacept (LEA29Y)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Efalizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15476300\">",
"      Alemtuzumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4586\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4586|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/2/26658\" title=\"figure 1\">",
"      Signals T cell activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/9/2194\" title=\"figure 2\">",
"      Overview T cell activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/58/15279\" title=\"figure 3\">",
"      Freedom primary endpoint",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4586|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/32/1547\" title=\"table 1\">",
"      Steroid compound dose equiv",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/63/12283\" title=\"table 2\">",
"      Baylor steroid protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/22/7532\" title=\"table 3\">",
"      Dosing formulation monitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/44/15042\" title=\"table 4\">",
"      Drug interactions with immunosuppressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/7/20603\" title=\"table 5\">",
"      Relative risk complication",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31530?source=related_link\">",
"      Clinical manifestations and natural history of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/28/37319?source=related_link\">",
"      Diagnosis of acute cellular rejection in liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/47/41718?source=related_link\">",
"      Treatment of acute cellular rejection in liver transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_12_30923="Pyrazinamide weight based dosing";
var content_f30_12_30923=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Weight-based dosing for pyrazinamide",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Frequency of administration",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Patient weight (kg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        40 to 55",
"       </td>",
"       <td class=\"subtitle2\">",
"        56 to 75",
"       </td>",
"       <td class=\"subtitle2\">",
"        76 to 90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Daily, mg",
"        <br/>",
"        (mg/kg)",
"       </td>",
"       <td class=\"centered\">",
"        1000",
"        <br/>",
"        (18.2 to 25.0)",
"       </td>",
"       <td class=\"centered\">",
"        1500",
"        <br/>",
"        (20.0 to 26.8)",
"       </td>",
"       <td class=\"centered\">",
"        2000*",
"        <br/>",
"        (22.2 to 26.3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrice weekly, mg",
"        <br/>",
"        (mg/kg)",
"       </td>",
"       <td class=\"centered\">",
"        1500",
"        <br/>",
"        (27.3 to 37.5)",
"       </td>",
"       <td class=\"centered\">",
"        2500",
"        <br/>",
"        (33.3 to 44.6)",
"       </td>",
"       <td class=\"centered\">",
"        3000*",
"        <br/>",
"        (33.3 to 39.5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Twice weekly, mg",
"        <br/>",
"        (mg/kg)",
"       </td>",
"       <td class=\"centered\">",
"        2000",
"        <br/>",
"        (36.4 to 50.0)",
"       </td>",
"       <td class=\"centered\">",
"        3000",
"        <br/>",
"        (40.0 to 53.6)",
"       </td>",
"       <td class=\"centered\">",
"        4000*",
"        <br/>",
"        (44.4 to 52.6)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Maximum doses regardless of weight.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_12_30923=[""].join("\n");
var outline_f30_12_30923=null;
var title_f30_12_30924="Causes genital bleeding by age";
var content_f30_12_30924=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Usual causes of abnormal genital bleeding in women by age group",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Neonates",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Estrogen withdrawal",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Premenarchal",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Foreign body",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Trauma, including sexual abuse",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Infection",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Urethral prolapse",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sarcoma botryoides",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ovarian tumor",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Precocious puberty",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Early postmenarche",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Anovulation (hypothalamic immaturity)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Bleeding diathesis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Stress (psychogenic, exercise induced)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pregnancy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Infection",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Reproductive years",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Anovulation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pregnancy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cancer",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Polyps, fibroids, adenomyosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Infection",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Endocrine dysfunction (PCOS, thyroid, pituitary adenoma)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Bleeding diathesis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Medication related (eg, contraceptive agents)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Perimenopausal",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Anovulation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Polyps, fibroids, adenomyosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cancer",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Menopause",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Atrophy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cancer",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Estrogen replacement therapy",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from APGO educational series on women's health issues. Clinical management of abnormal uterine bleeding. Association of Professors of Gynecology and Obstetrics, May 2002.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_12_30924=[""].join("\n");
var outline_f30_12_30924=null;
var title_f30_12_30925="Primary secondary syphilis US";
var content_f30_12_30925=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Primary and Secondary Syphilis - Reported Rates: United States, 1970-2000 and the Healthy People Year 2010 Objective",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 250px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Note: The Healthy People 2010 (HP2010) objective for primary and secondary syphilis is 0.2 case per 100,000 population",
"    </div>",
"    <div class=\"reference\">",
"     From the Centers for Disease Control and Prevention (CDC), Division of STD Prevention, website, www.cdc.gov.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_12_30925=[""].join("\n");
var outline_f30_12_30925=null;
var title_f30_12_30926="Conduit leak B";
var content_f30_12_30926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Conduit leak at urethral anastomosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiograph showing percutaneous stent placed into conduit, which allowed drainage and subsequent healing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_12_30926=[""].join("\n");
var outline_f30_12_30926=null;
var title_f30_12_30927="BFM regimen";
var content_f30_12_30927=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F81231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F81231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Children's Cancer Group treatment schema for Pediatric Acute Lymphoblastic Leukemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\" colspan=\"2\">",
"            Standard therapy (CCG-BFM)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_left\">",
"            Treatment",
"           </td>",
"           <td class=\"subtitle2_left\">",
"            Dose",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle3_left\" colspan=\"2\">",
"            Consolidation phase (5 weeks)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Prednisone",
"           </td>",
"           <td>",
"            7.5 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            , day 0; 3.75 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            , days 1, 2",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Cyclophosphamide",
"           </td>",
"           <td>",
"            1000 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            IV, days 0, 14",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Mercaptopurine",
"           </td>",
"           <td>",
"            60 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            orally, days 0-27",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Vincristine",
"           </td>",
"           <td>",
"            1.5 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            IV, days 14, 21, 42, 49",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Cytarabine",
"           </td>",
"           <td>",
"            75 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            IV, days 1-4, 8-11, 15-18, 22-25",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Intrathecal methotrexate*",
"           </td>",
"           <td>",
"            12 mg, days 1, 8, 15, 22",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Radiotherapy&bull;",
"           </td>",
"           <td>",
"            Cranial, 1800 cGy; cranial, 2400 cGy, and spinal, 600 cGy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle3_left\" colspan=\"2\">",
"            Interim maintenance phase (8 weeks)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Mercaptopurine",
"           </td>",
"           <td>",
"            60 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            orally, days 0-41",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Methotrexate",
"           </td>",
"           <td>",
"            15 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            orally, days 0, 7, 14, 21, 28, 35",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle3_left\" colspan=\"2\">",
"            Delayed intensification phase (7 weeks)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3_start\" colspan=\"2\">",
"            Reinduction phase (4 weeks)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Dexamethasone",
"           </td>",
"           <td class=\"sublist_other\">",
"            10 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            orally, days 0-20, then taper for 7 days",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Vincristine",
"           </td>",
"           <td class=\"sublist_other\">",
"            1.5 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            IV, days 0,14, 21",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Doxorubicin",
"           </td>",
"           <td class=\"sublist_other\">",
"            25 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            IV, days 0, 7, 14",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3_start\" colspan=\"2\">",
"            Reconsolidation phase (3 weeks)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Asparaginase",
"           </td>",
"           <td class=\"sublist_other\">",
"            6000 units/m",
"            <sup>",
"             2",
"            </sup>",
"            IM, days 3, 5, 7, 10, 12, 14",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Vincristine",
"           </td>",
"           <td class=\"sublist_other\">",
"            1.5 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            IV, days 42, 29",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Cyclophosphamide",
"           </td>",
"           <td class=\"sublist_other\">",
"            1000 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            IV, days 28",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Thioguanine",
"           </td>",
"           <td class=\"sublist_other\">",
"            60 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            orally, days 28-41",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Cytarabine",
"           </td>",
"           <td class=\"sublist_other\">",
"            75 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            SC or IV, days 29-32, 36-39",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Intrathecal methotrexate*",
"           </td>",
"           <td class=\"sublist_other\">",
"            12 mg, days 29, 36",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle3_left\" colspan=\"2\">",
"            Long-term maintenance phase (12 weeks)&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Vincristine",
"           </td>",
"           <td>",
"            1.5 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            IV, days 0, 28, 56",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Prednisone",
"           </td>",
"           <td>",
"            40 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            orally, days 0-4, 28-32, 56-60",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Mercaptopurine",
"           </td>",
"           <td>",
"            75 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            orally, days 0-83",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Methotrexate",
"           </td>",
"           <td>",
"            20 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            orally, days 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, 77",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Intrathecal methotrexate*",
"           </td>",
"           <td>",
"            12 mg, day 0",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\" colspan=\"2\">",
"            Augmented BFM therapy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_left\">",
"            Treatment",
"           </td>",
"           <td class=\"subtitle2_left\">",
"            Dose",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle3_left\" colspan=\"2\">",
"            Consolidation phase (9 weeks)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Cyclophosphamide",
"           </td>",
"           <td>",
"            1000 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            IV, days 0, 28",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Cytarabine",
"           </td>",
"           <td>",
"            75 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            SC or IV, days 1-4, 8-11, 29-32, 36-39",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Mercaptopurine",
"           </td>",
"           <td>",
"            60 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            orally, days 0-13, 28-41",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Vincristine",
"           </td>",
"           <td>",
"            1.5 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            IV, days 14, 21, 42, 49",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Asparaginase",
"           </td>",
"           <td>",
"            6000 units/m",
"            <sup>",
"             2",
"            </sup>",
"            IM, days 14,16, 18, 21, 23, 25, 42, 44, 46, 49, 51, 53",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Intrathecal methotrexate*",
"           </td>",
"           <td>",
"            12 mg, days 1, 8, 15, 22",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Radiotherapy&bull;",
"           </td>",
"           <td>",
"            Cranial, 1800 cGy; cranial, 2400 cGy, and spinal, 600 cGy; testicular, 2400 cGy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle3_left\" colspan=\"2\">",
"            Interim maintenance phase (8 weeks)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Vincristine",
"           </td>",
"           <td>",
"            1.5 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            IV, days 0, 10, 20, 30, 40",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Methotrexate",
"           </td>",
"           <td>",
"            100 mg/mg",
"            <sup>",
"             2",
"            </sup>",
"            IV, days 0, 10, 20, 30, 40 (escalate by 50 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            per dose)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Asparaginase",
"           </td>",
"           <td>",
"            15,000 units/m",
"            <sup>",
"             2",
"            </sup>",
"            IM, days 1, 11, 21, 31, 41",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle3_left\" colspan=\"2\">",
"            Delayed intensification I phase (8 weeks)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3_start\" colspan=\"2\">",
"            Reinduction phase (4 weeks)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Dexamethasone",
"           </td>",
"           <td class=\"sublist_other\">",
"            10 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            orally, days 0-20, then taper for 7 days",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Vincristine",
"           </td>",
"           <td class=\"sublist_other\">",
"            1.5 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            IV, days 0, 14, 21",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Doxorubicin",
"           </td>",
"           <td class=\"sublist_other\">",
"            25 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            IV, days 0, 7, 14",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3_start\" colspan=\"2\">",
"            Reconsolidation phase (4 weeks)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Asparaginase",
"           </td>",
"           <td class=\"sublist_other\">",
"            6000 units/m",
"            <sup>",
"             2",
"            </sup>",
"            IM, days 3, 5, 7, 10, 12, 14",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Vincristine",
"           </td>",
"           <td class=\"sublist_other\">",
"            1.5 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            IV, days 42, 49",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Cyclophosphamide",
"           </td>",
"           <td class=\"sublist_other\">",
"            1000 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            IV, day 28",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Thioguanine",
"           </td>",
"           <td class=\"sublist_other\">",
"            60 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            orally, days 28-41",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Cytarabine",
"           </td>",
"           <td class=\"sublist_other\">",
"            75 mg/m",
"            <sup>",
"             2&nbsp;",
"            </sup>",
"            per day&nbsp;SC or IV, days 29-32, 36-39",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Intrathecal methotrexate*",
"           </td>",
"           <td class=\"sublist_other\">",
"            12 mg, days 29, 36",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Asparaginase",
"           </td>",
"           <td class=\"sublist_other\">",
"            6000 units/m",
"            <sup>",
"             2",
"            </sup>",
"            IV, days 42, 44, 46, 49, 51, 53",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle3_left\" colspan=\"2\">",
"            Interim maintenance II phase (8 weeks)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Vincristine",
"           </td>",
"           <td>",
"            1.5 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            IV, days 0, 10, 20, 30, 40",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Methotrexate",
"           </td>",
"           <td>",
"            100 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            IV, days 0, 10, 20, 30, 40 (escalate by 50 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            per dose)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Asparaginase",
"           </td>",
"           <td>",
"            15,000 units/m",
"            <sup>",
"             2",
"            </sup>",
"            IM, days 1, 11, 21, 31, 41",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Intrathecal methotrexate*",
"           </td>",
"           <td>",
"            12 mg, days 0, 20, 40",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle3_left\">",
"            Delayed intensification II phase (8 wk)",
"           </td>",
"           <td>",
"            Same as for delayed intensification I phase",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle3_left\" colspan=\"2\">",
"            Long-term maintenance phase (12 weeks)&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Vincristine",
"           </td>",
"           <td>",
"            1.5 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            IV, days 0, 28, 56",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Prednisone",
"           </td>",
"           <td>",
"            60 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            orally, days 0-14, 28-32, 56-60",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Mercaptopurine",
"           </td>",
"           <td>",
"            75 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            orally, days 0-83",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Methotrexate",
"           </td>",
"           <td>",
"            20 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            orally, days 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, 77",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Intrathecal methotrexate*",
"           </td>",
"           <td>",
"            12 mg, day 0",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Induction was as follows: vincristine, 1.5 mg/m",
"    <sup>",
"     2",
"    </sup>",
"    per week for 4 weeks; daunomycin, 25 mg/m",
"    <sup>",
"     2",
"    </sup>",
"    per week for 4 weeks; prednisone, 60 mg/m",
"    <sup>",
"     2",
"    </sup>",
"    per day for 28 days; asparaginase, 6000 units/m",
"    <sup>",
"     2",
"    </sup>",
"    IM 3 times a week for 9 doses; intrathecal cytarabine on day 0; and intrathecal methotrexate on day 14.",
"    <div class=\"footnotes\">",
"     IM: intramuscular, SC: subcutaneous, IV: intravenous",
"     <br>",
"      * Patients with CNS disease at diagnosis did not receive intrathecal methotrexate on days 15 and 22 of consolidation therapy.",
"      <br>",
"       &bull; During the first 2 weeks of consolidation therapy, patients without CNS disease at diagnosis received 1800 cGy of cranial radiotherapy in 10 fractions; patients with CNS disease at diagnosis received 2400 cGy to the cranial midplane in 12 fractions and 600 cGy to the spinal cord in 3 fractions. In the augmented therapy group, patients with testicular enlargement at diagnosis received 2400 cGy bilateral testicular radiation in 8 fractions.",
"       <br>",
"        &Delta; The cycles of maintenance therapy were repeated until the total duration of therapy, beginning with the first interim maintenance period, reached 2 years for girls and 3 years for boys.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     This research was originally published in Blood. Stock, W, La, M, Sanford, B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 2008; 112:1646. Copyright &copy;2008 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_12_30927=[""].join("\n");
var outline_f30_12_30927=null;
